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4. Introduction 
4.1 Type 2 diabetes and coronary artery disease. 
There is a close relationship between type 2 diabetes and coronary artery disease (CAD) [1]. 
Despite the improving survival rate in patients with CAD, the prognosis for individuals with 
CAD and type 2 diabetes remains poor [2]. The risk of developing CAD is increased by 2-3 
fold in individuals with type 2 diabetes and CAD accounts for approximately 70 % of total 
mortality [3,4]. Moreover, patients with diabetes without previous myocardial infarction (MI) 
have similar risk for MI as patients without diabetes with a previous MI [5]. It is estimated 
that 50 % of subjects with newly diagnosed type 2 diabetes already have CAD and about 10-
20 % of patients presenting with an acute MI have known type 2 diabetes [6]. Additionally, 
several prospective studies have reported a high prevalence of newly diagnosed impaired 
fasting glucose (IFG), impaired glucose tolerance (IGT) and type 2 diabetes in patients with 
acute MI without previously known diabetes (Table 2) [7-9]. The primary objective of the 
present work was to study the association between MI and glucometabolic disturbances in 
patients with acute ST-elevation myocardial infarction (STEMI) without previously known 
diabetes. 
 
4.2 Abnormal glucose regulation
Globally, the number of people diagnosed with diabetes was estimated to 285 million in 2010 
[10]. Many individuals are undiagnosed and the prevalence will increase exponentially 
because of the change in lifestyle with increasing obesity and reduced physical activity. 
Moreover, the prevalence seems to increase more in developing than in developed countries 
[10]. In Norway, about 90000-120000 people were estimated to have diabetes in 2004, and 
about the same number were considered to be undiagnosed [11].  
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Type 2 diabetes is a chronic disease that develops when the pancreas fails to produce enough 
insulin or the body cannot utilize the insulin produced efficiently [12]. Type 2 diabetes can be 
insulin dependent according to metabolic control, or insulin independent according to 
acceptable control by non–pharmacological methods or drugs other than insulin [12]. 
Impaired glucose regulation (IFG, IGT) is classified as a metabolic state intermediate between 
normal glucose regulation and diabetes [12]. In the present work the term abnormal glucose 
regulation defined as the sum of IFG, IGT and type 2 diabetes will be used. Glucometabolic 
status is usually classified according to the World Health Organization (WHO) or the 
American Diabetes Association (ADA) criteria [12,13]. In the present work the WHO criteria 
from 2005 have been followed [14].  
 
4.3 Oral glucose tolerance test. 
Post-load hyperglycaemia reflects the acute increase in blood glucose after glucose loading, 
whereas fasting glucose concentration after an overnight fast reflects mostly hepatic glucose 
production [15]. Fasting plasma glucose and glucose 2-hour after loading with 75 g glucose 
are both measures of glucometabolic disturbances and a fasting value of 7.0 mmol/L has been 
suggested to represent a similar degree of hyperglycaemia as a 2-h value of 11.1 mmol/L, but 
the tests are not concordant [16]. Thus, a patient could be diagnosed with diabetes using one 
test but not the other [16]. In epidemiological studies the oral glucose tolerance test (OGTT) 
has been accepted as a screening tool and retesting is rarely performed. However, in clinical 
practice when diagnosing asymptomatic individuals, retesting to confirm the diagnosis is 
required [14]. WHO recommend, whereas ADA do not recommend, the use of an OGTT in 
routine clinical practice [12,13].  
European guidelines on diabetes, prediabetes, and cardiovascular disease (CVD) from 2007 
recommend that patients without previously known diabetes, but with established CVD 
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should be investigated with an OGTT [17]. However, there exists no consensus about the 
timing of an OGTT after acute MI [17]. The European guidelines rely mainly on the Swedish 
GAMI (Glucose Tolerance in Patients with Acute Myocardial Infarction) study, which was 
the first study to perform an OGTT in patients with acute MI without previously known 
diabetes and admission glucose <11.1 mmol/l [7]. The OGTT was performed the fourth or 
fifth day after hospital admission (before discharge) and the test was repeated at three-month 
follow-up. The investigators concluded that the OGTT performed before discharge provided 
reliable information on long-term glucometabolic state [18]. The GAMI results, were 
however, not confirmed by similar studies before incorporated into the guidelines. 
4.4 Acute myocardial infarction
The survival rates are improving for patients with CVD, however, CVD remains to be the 
leading cause of death worldwide both in men and women. In 2004, about 17 million people 
died of CVD globally. Sedentary lifestyle, unhealthy diet, smoking, hypertension, 
hypercholesterolemia and a family history of CVD seem to be the main causes of CVD [19].  
CAD is a chronic disease with stable or unstable periods [20]. Acute coronary syndromes are 
clinically defined as unstable angina pectoris, non-ST-elevation myocardial infarction 
(NSTEMI) or STEMI and are characterized by myocardial ischemia and / or cell death due to 
perfusion imbalance between supply and demand [20,21]. Acute STEMI is defined according 
to the universal definition of MI as typical rise and fall of the cardiac biomarker troponin T 
(TnT) with at least one value above the 99th percentile of the upper reference limit in patients 
presenting with symptoms of ischemia together with electrocardiogram (ECG) changes 
indicative of new ST elevation at the J-point in two contiguous leads with the cut-off points: 
0.2 mV in men or 0.15 mV in women in leads V2–V3 and/or 0.1 mV in other leads or new 
left bundle-branch block [20]. 
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4.5 Prognostic aspects 
It is well established that patients with acute MI and diabetes have a worse short- and long-
term prognosis compared to patients without diabetes, and that this association seems to be 
independent of traditional cardiovascular risk factors [5,22,23]. Moreover, in multiple large 
prospective studies both admission and fasting blood glucose, regardless of diabetic status, 
have been shown to be independent predictors of both in-hospital and long-term outcome in 
patients with acute MI [24-29]. The association between newly diagnosed impaired glucose 
tolerance and clinical outcome after an acute MI is less clear. In a mixed population with both 
acute and stable CAD, no association between impaired glucose regulation (IFG, IGT) and 
mortality was found after one-year follow-up [30]. However, in the follow-up of the GAMI 
trial, newly diagnosed abnormal glucose tolerance (IGT, T2DM) was associated with poor 
prognosis after three-year follow-up [31]. In spite of diverging results, patients with CAD and 
impaired glucose regulation as well as type 2 diabetes have been categorized as high-risk 
patients important to identify as early as possible.  
4.6 Pathophysiological aspects 
4.6.1 Abnormal glucose regulation 
Type 2 diabetes is a metabolic disorder characterized by hyperglycaemia, which arises from 
insufficient pancreatic insulin secretion and insulin resistance in peripheral tissue [32]. Insulin 
is a hormone that controls the glucose homeostasis in humans. It promotes glucose uptake and 
glycogen synthesis in fat and muscles tissue and prevents glucose production by inhibition of 
glycogenolysis and gluconeogenesis in the liver [33]. Skeletal muscle is responsible for more 
than 80 % of insulin stimulated glucose utilization [34]. The glucose uptake in muscle tissue 
is a complex process. Insulin stimulates the phosphorylation of the insulin receptor substrate 
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that activate a series of intracellular signal molecules resulting in translocation and activation 
of GLUT-4 to the cell membrane, resulting in increased glucose uptake [32].  
The progression from normal to impaired glucose regulation (IFG, IGT) and subsequently 
type 2 diabetes is associated with decreasing insulin action in peripheral tissue and impaired 
insulin secretion due to progressive pancreatic beta cell dysfunction (Figure 1) [35]. In a 
condition with insulin resistance, the capacity of insulin to stimulate glucose uptake and 
utilization is reduced [32]. Skeletal muscles are the major sites of peripheral insulin resistance 
and defects in the intracellular insulin signalling sequences results in reduced GLUT-4 
translocation, activation, and glucose uptake [32].  
 
Figure 1. Progression from insulin resistance to type 2 diabetes. Modified from Laakso and 
Kuusisto [36].  
 
Diagnosis of diabetes
DiabetesImpaired glucose tolerance
Fast blood glucose
Microvascular
complications
Macrovascular 
complications
Insulin resistance
Years
Time
Endogenous insulin
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4.6.2 Atherosclerosis 
Atherosclerosis is a chronic systemic disease that occurs in large and medium-sized arteries 
and may cause clinical symptoms from the brain, heart and extremities [37]. Coronary 
atherosclerosis is asymmetrical lesions with focal thickening of the arterial intima consisting 
of cells, connective-tissue elements, lipids, and debris often described as atherosclerotic 
plaques [37-39]. An occlusion of the coronary artery occurs either by endothelial erosion or 
plaque rupture that arise most often in the thinnest part of the fibrous cap exposing 
prothrombotic material to the circulation, triggering a platelet rich thrombus formation within 
the atherosclerotic lesion and an acute MI may occur [21,40]. Inflammation has been shown 
to be involved in the formation, progression, rupture of atherosclerotic plaques, and in the 
healing of the ischemic myocardium. Monocyte infiltration into the vascular intima is central 
in the initial phase of the atherosclerotic process [39].  
 
4.6.3 Atherosclerosis and abnormal glucose regulation 
Type 2 diabetes and atherosclerosis are multifactorial conditions, which may share 
cardiovascular risk factors associated with the metabolic syndrome [41]. Although, the 
association between type 2 diabetes and atherosclerotic disorders are not fully understood, 
chronic hyperglycaemia, insulin resistance and dyslipidemia have been shown to make 
arteries susceptible to atherosclerosis [42]. It has also been suggested that atherosclerosis, 
type 2-diabetes and metabolic syndrome are characterized by chronic inflammation [43,44]. 
During normal conditions the vascular endothelium does not support adhesion and 
transmigration of blood cells [45]. However, the endothelium might become dysfunctional 
and leaky by exposure to different stimuli such as hyperglycaemia, insulin resistance, 
inflammation, hypertension, elevated levels of free radicals, and accumulation of modified 
lipids [42].  
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4.6.4 Inflammation
Inflammation has been suggested to be the bridging link between abnormalities in glucose 
metabolism and atherosclerotic disorders [38]. On the cell surface of activated endothelium, 
different adhesion molecules are expressed [43]. Circulating blood cells like monocytes and 
lymfocytes roll along the vascular surface and adhere at the site of endothelial activation. 
Different pro-inflammatory cytokines stimulate endothelial cells, smooth muscle cells and 
macrophages to release chemokines responsible for the recruitment of monocytes and 
lymfocytes to sites of inflammation [42]. Chemokines, such as monocyte chemoattractant 
protein-1 (MCP-1) and interleukin-8 promotes the transmigration of monocytes and 
lymfocytes to the intima through activation of the interendothelial junctions. In the intima, 
monocytes are differentiated in to macrophages. Scavenger and toll-like receptors on 
macrophages regulate this process. The scavenger receptors mediate the uptake of oxidized 
low density lipoprotein (LDL) particles leading to the formation of foam cells, while toll-like 
receptors promote signalling cascades that lead to inflammatory activation and initiation of 
atherosclerosis [46].  
In endothelial cells the glucose uptake is mediated by facilitative diffusion independent of 
insulin action, if overfed they cannot downregulate the influx of nutrients [47]. During 
hyperglycaemic periods intracellular glucose overload causes uncontrolled overproduction of 
superoxide within the mithochondrial electron transport chain. This may have multiple 
functional and pathogenetic consequences such as initiating endothelial dysfunction, and 
vascular inflammation [47,48].  
The hyperglycaemia-induced inflammatory process in the atherosclerotic wall may lead to 
elevated levels of circulating inflammatory cytokines and chemokines that can be measured 
[38,39]. C-reactive protein (CRP), which is produced in the liver by interleukin-6 stimulation, 
is well known as an acute-phase reactant, and circulating levels of CRP have been identified 
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to be a non-specific biomarker of low-grade inflammation [49-53]. Other circulating 
inflammatory variables such as the chemokine MCP-1 have been shown to be elevated after 
an acute MI, suggesting that mononuclear cells may play an important role in the early phase 
of the pathogenesis of an acute MI [54].  
    
4.6.5 Haemostasis 
As well as being a pro-inflammatory state, type 2 diabetes has also been shown to be a 
prothrombotic condition due to platelet dysfunction, suppressed fibrinolysis and enhanced 
coagulation [55]. The normal vascular endothelium release substances like prostacyclin and 
nitric oxide that promote a vasodilatory and antithrombotic condition [56]. Additionally, 
insulin has been shown to antagonise platelet activation/aggregation by cell surface receptors 
[57,58]. However, in patients with insulin-resistance the platelet response to insulin, nitric 
oxide and prostacyclin seems inadequate [57,58]. Moreover, in type 2 diabetic patients, 
platelets seem to adhere to the endothelium and aggregate more rapidly than in healthy 
subjects [57,59-61].  
In patients with insulin resistance and CAD the fibrinolytic activity is suppressed mostly due 
to elevated levels of plasminogen activator inhibitor-1 (PAI-1) [33,62]. During weight loss the 
levels of PAI-1 have been reported to decrease [63,64]. Furthermore, PAI-1 is an acute phase 
protein known to increase rapidly in response to acute illness [65].  
PAI-1 is the main inhibitor of the fibrinolytic system acting by inhibiting tissue plasminogen 
activator (t-PA), leading to reduced activation of plasminogen to plasmin and as a 
consequence, less available plasmin, which is required for lysis of fibrin [66]. Circulating 
levels of PAI-1 reflect secretion and release from several sources, including the liver, adipose 
tissue, endothelium and the -storage granules of platelets [65]. PAI-1 circulates in plasma, in 
an active form and in an inactive complex with t-PA [65]. In patients with insulin resistance, 
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type 2 diabetes and CAD, circulating PAI-1 levels have been shown to correlate with levels of 
insulin, triglycerides, body mass index, and blood pressure, indicating that PAI-1 seems to be 
an important part of the cluster of risk factors leading to CAD [55].  
Tissue plasminogen activator is the main activator of the fibrinolytic system acting by 
converting plasminogen to plasmin (Figure 2) [55]. t-PA is produced and secreted mainly by 
endothelial cells and has a half-life of about 2 min in the circulation [66]. In the absence of 
fibrin, t-PA activates plasminogen at a slow rate, but when t-PA and plasminogen both bind to 
fibrin the catalytic effect of t-PA enhances about 1000-fold [55]. Most of the secreted t-PA 
will be inactivated by PAI-1 before it binds fibrin due to the high affinity to PAI-1. The most 
common method used for t-PA measurements is t-PA antigen including both free t-PA and t-
PA in complex with PAI-1 [66]. Elevated levels of t-PA antigen appear to be beneficial due to 
an increased potential to generate plasmin resulting in increased fibrinolysis. However, 
elevated levels of t-PA antigen mainly reflect the level of PAI-1 and appear rather to be 
harmful than beneficial and are claimed to be a marker of endothelial dysfunction and 
atherosclerosis [55,67]. 
Furthermore, patients with diabetes mellitus are known to have a prothrombotic phenotype 
based on both measured biochemical abnormalities and a high frequency of vascular clinical 
events [68]. Hyperglycaemia has been reported to correlate with increase in coagulation 
factors both in patients with diabetes and in normal subjects in whom a hyperglycaemic state 
has been initiated [69-71]. Experimentally induced hyperglycaemia in healthy subjects has 
been shown to increase FVII clotting activity [72] and soluble tissue factor [73]. Additionally, 
a direct glycation of coagulation factors during hyperglycaemia have been reported to alter 
their activity [74].  
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Figure 2. Fibrinolysis (simplified), blue arrows denote stimulation, and red arrows inhibition. 
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4.7 Rationale for the study. 
When the present project was initiated, very little was known about the prevalence of 
abnormal glucose regulation in Norwegian patients with CAD and especially in patients with 
STEMI. In addition, according to institutional guidelines, routine use of OGTT to screen for 
glucometabolic perturbations was not a part of common routine in patients with CAD. 
However, in one clinical trial in Norway in which an OGTT was performed in patients 
hospitalized with CAD, cerebrovascular disease or peripheral artery disease, glucometabolic 
disturbance was found in 49 %, 55% and 57% of the patients, respectively [75]. Our research 
group performed a pilot study on 100 non-diabetic patients with acute MI hospitalized at Oslo 
University Hospital, Ullevål and found that about half of the patients had abnormal glucose 
regulation classified by an OGTT performed early after primary percutaneous coronary 
intervention (PCI) [76]. Furthermore, European guidelines recommended OGTT as a 
screening tool for all patients with CAD, but did not specify the timing of OGTT after an 
acute MI [17]. As the recent European Guidelines were mainly based on a single clinical 
study regarding the timing of an OGTT in MI patients, we also wanted to evaluate the 
reproducibility of an OGTT in patients with STEMI by repeating the test during stable 
 18
conditions. In addition, type 2 diabetes has been shown to be a prothrombotic and a pro-
inflammatory condition [41,74] and we wanted to investigate whether newly detected 
abnormal glucose regulation was associated with inflammatory and haemostatic variables in 
patients with acute STEMI without previously known diabetes, in order to obtain new insights 
into mechanisms involved in these closely related diseases. Based on these considerations the 
present work was initiated and carried out.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 19
5. Aims of the study 
 to study the prevalence of impaired fasting glucose, impaired glucose tolerance and 
type 2 diabetes early in-hospital and at three-month follow-up, in a primary PCI 
treated STEMI population without known diabetes. Furthermore, to evaluate the 
reliability of an OGTT-based glucometabolic classification early in-hospital in order 
to predict glucometabolic disturbance defined by a repeated OGTT at three-month 
follow-up (Paper I).  
 to elucidate a possible association between HbA1c, admission glucose and fasting 
glucose identified during the initial hospitalization and abnormal glucose regulation 
classified by an OGTT at three-month follow-up (Paper I). 
 
 to investigate clinical outcome in patients with acute STEMI after exclusion of 
patients with known diabetes (Paper II). 
  to evaluate whether abnormal glucose regulation classified by an OGTT in-hospital or 
at three-month follow-up was associated with poor long-term prognosis after acute 
STEMI (Paper II). 
 
 to study potential associations between circulating levels of selected inflammatory 
markers and plasma glucose levels measured during an acute STEMI (Paper III). 
 to identify any associations between circulating levels of inflammatory markers 
measured during an acute STEMI and abnormal glucose regulation classified by an 
OGTT at three month follow-up in the same cohort (Paper III). 
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 to investigate any associations between circulating levels of selected haemostatic 
variables measured in-hospital and the presence of abnormal glucose regulation 
classified at three-month follow-up (Paper IV). 
 to explore changes in measured haemostatic variables from baseline to follow-up in 
patients with or without abnormal glucose regulation classified at follow-up (Paper 
IV). 
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6. Material and methods
6.1 Study subjects and design 
All papers report results from the same cohort of 224 patients with a primary PCI treated 
STEMI admitted to the coronary care unit at Oslo University Hospital, Ullevål, Oslo, Norway, 
between November 2005 and May 2007 (Figure 3).  
 
Figure 3. Study population.  
 
At enrolment, patients were clinical and hemodynamically stable, without persistent 
glyseroltrinitrat infusion, chest pain, nausea or symptoms of heart failure. Patients with 
previously known diabetes, persistent hyperglycaemia, serum creatinine concentration  200 
umol/L, or age > 85 years were excluded.  
 
 
 
 
201 patients repeated an OGTT
at 3-month follow-up
1 patient died
224 patients included
223 patients participated
at long-term follow-up
Haemostatic variables were
measured in 199 patients 
22 patients were unwilling
to repeat  an OGTT
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Figure 4. Study design  
CE; clinical examination, I/E; inclusion/exclusion, SPECT; Single Photon Emission 
Computed Tomography.  
 
 
 
The study design is shown in Figure 4. The first OGTT was performed after an overnight fast, 
before transfer from the coronary care unit back to the referring hospitals.  
The second OGTT was performed after an overnight fast in a stable condition at three-month 
follow-up. The Regional Ethics Committee approved the study and all patients gave written 
informed consent. The study is registered at www.clinicaltrials.gov, NCTC00926133. 
 
Paper II was a follow-up study. The date of inclusion was set to the date when the primary 
PCI was performed. In June 2009, at a median follow up time of 33 months, the patients were 
contacted and interviewed by telephone, regarding their health status, and any hospital 
admissions. Final closing date was set to August 1st 2009. The primary endpoint of the study 
was defined as the composite of the first event of non-fatal myocardial re-infarction, recurrent 
ischemia causing hospital admission, stroke, and all cause mortality. An end-point committee 
classified the end-points according to the hospital records, and death certificates were 
obtained from the Norwegian Death certificate Registry.  
 
 
Admission
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In paper III fasting blood samples drawn in-hospital mainly in the first morning (between 
8:00-10:00 am) after the acute MI were used for determination of a panel of inflammatory 
variables known to be of importance in the atherosclerotic process. 
 
In paper IV fasting blood samples drawn mainly the first morning after the acute MI and in a 
stable condition at three-month follow-up (between 8:00-10:00 am) were used for 
determination of the selected haemostatic variables. 
 
 
6.2 Classification of glucometabolic state 
A standardised OGTT (75g glucose in 200 ml water with plasma glucose measurements at 0 
and 120 min) was performed in-hospital (median 16.5 hours after acute PCI) and at an 
outpatient visit three months later. The classification of glucometabolic state was based on the 
result of the OGTT and the patients were divided into one of the following four categories 
according to the WHO criteria (Table 1) [14]. 
 
 Table 1 Criteria used for glucometabolic classification according to WHO 2005 [14]. 
Glucometabolic category Classification criteria 
(plasma glucose in mmol/l)
Normal glucose tolerance (NGT)  
Fasting glucose <6.1 
2-hour glucose <7.8 
Impaired fasting glucose (IFG)  
Fasting glucose 6.1 and <7.0 
2-hour glucose <7.8 
Impaired glucose tolerance (IGT)  
Fasting glucose  <7.0 
2-hour glucose 7.8 and  <11.1 
Diabetes mellitus (T2DM)  
Fasting glucose  7.0 
2-hour glucose 11.1 
The term abnormal glucose regulation was defined as the sum of IFG, IGT and T2DM.  
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6.3 Classification of acute STEMI.  
STEMI was defined according to the universal definition of MI as typical rise and fall of the 
cardiac biomarker troponin T (TnT) with at least one value above the 99th percentile of the 
upper reference limit in patients presenting with symptoms of ischemia together with ECG 
changes indicative of new ST elevation at the J-point in two contiguous leads with the cut-off 
points: 0.2 mV in men or 0.15 mV in women in leads V2–V3 and/or 0.1 mV in other leads or
new left bundle-branch block [20]. 
 
6.4 Laboratory methods 
Admission plasma glucose was analysed from blood samples drawn in the catheterisation 
laboratory as soon as possible after PCI. Further blood samples were drawn at inclusion and at 
three-month follow-up in a fasting condition between 8-10 a.m. Plasma glucose, HbA1c, and 
other routine analyses were determined by use of conventional methods. Serum cardiac 
specific Troponin T (TnT) was measured by electrochemiluminescence technology for 
quantitative measurement as described in paper I. Circulating levels of serum insulin, serum 
proinsulin, and inflammatory and haemostatic variables, were measured by commercially 
available enzyme immunoassay, as described in detail in paper II, III and IV. All blood 
samples except routine samples were stored at -80C until analysis. 
 
 
Left ventricular ejection fraction and infarct size expressed as percent of left ventricular mass, 
were assessed at rest at three-month follow-up by Single Photon Emission Computed 
Tomography imaging with technetium 99 m-tetrofosmin. The method is described in detail in 
paper II. 
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6.6 Statistics 
The study design was a prospective observational cohort study. Due to skewness in most of 
the measured variables, non-parametric statistics were used throughout. Continuous variables 
are presented as median values with 25th, 75th percentiles and categorical variables as 
proportions. Differences among groups were analysed by Mann-Whitney test for continuous 
variables and the chi-squared test for categorical data. The null hypothesis was rejected if the 
p-value was below 0.05. The STROBE guidelines were followed [77]. Statistical analyses 
were performed using Epi-info software (2005, version 3.3.2) except for Spearman correlation 
coefficient and multiple linear regressions analyses that were made using SPSS version 6.0 
for windows (SPSS Inc., Chicago, Illinois, USA). 
 
In paper I, III and IV an explanatory strategy was followed. A potential independent 
association between different exposition variables and outcome (disease) were studied. 
Outcome was defined as abnormal glucose regulation. All exposition variables were 
dichotomized in the model. Continuous exposition variables were dichotomised into high and 
low levels based on a linear trend analysis across quartiles with identification of the cut off 
point. Other traditional risk factors that were not a part of the causal chain (exposition to 
outcome) were analyzed as potential confounders or effect modifiers on this association. The 
Mantel-Haenszel method (a stratification model) was used to quantify potential confounders 
based on the assumption that the true exposition – outcome odds ratio is the same in each 
stratum, and that the reason for differences in the observed odds ratios between strata is only 
sampling variations. However, if the effect of exposition on outcome varies in the two strata 
according to a risk factor, heterogeneity between strata is present and the risk factor is 
identified as an effect modifier and not a confounder. The Breslow and Day test of 
heterogeneity was used to highlight potential effect modification before quantifying potential 
 26
confounders by the Mantel-Haenszel model [78]. Potential confounders that were associated 
with the exposition and / or outcome with a p-value <0.2, were included in the model. 
Finally, logistic regression models, including backward elimination procedures were 
performed to adjust for potential confounders on the association between exposition and 
outcome.  
Paper II was a follow-up study. Both univariate and multivariate analyses of this cohort with 
censored data were performed (Kaplan–Meier survival, Log-Rank test and Cox proportional 
hazard models).  
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7. Summary of results 
7.1 Paper I 
We investigated the prevalence of abnormal glucose regulation in a primary PCI treated 
STEMI population without known diabetes by performing an OGTT early in-hospital and at 
three-month follow-up. The prevalence of abnormal glucose regulation in-hospital and at 
three month was 47% and 25%, respectively. The observed reproducibility of the OGTT 
performed in-hospital and when repeated after three-month follow-up was poor. Only 54% of 
the patients were classified into the same glucometabolic state at both occasions. 
Additionally, we studied a potential association between HbA1c, admission glucose and 
fasting glucose measured during the acute STEMI and abnormal glucose regulation classified 
by an OGTT at three-month follow-up. High levels of HbA1c, as well as admission glucose 
were associated with abnormal glucose regulation classified three months later with an 
adjusted odds ratio of 3.8 (95% CI 1.8, 7.8) and 2.2 (1.0, 4.3), respectively. High levels of 
fasting glucose were associated with abnormal glucose regulation with an adjusted odds ratio 
of 5.5 (2.0, 15.1), but only in patients with small or medium-sized MI (TnT<8.80 ug/L). 
 
7.2 Paper II 
We prospectively followed the cohort for a median time of 33 months ((25, 75 % percentiles) 
27, 39). In the total population the long-term clinical outcome was excellent with a low event-
rate. Subsequently, clinical outcome were correlated to the glucometabolic condition found. 
The results from the OGTT performed early in-hospital and at three months follow-up were 
both correlated to clinical events. The composite endpoint was defined as all cause mortality, 
non-fatal re-infarction, stroke and recurrent ischemia causing hospital admission. No 
significant difference in survival free of composite end-point was found between the groups 
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when classified either by an OGTT in-hospital or at three-month follow-up (Log-Rank p=0.38 
and p=0.26, respectively). 
 
7.3 Paper III
We investigated a potential association between the circulating inflammatory markers and 
hyperglycaemia measured during the acute STEMI. No significant associations were 
observed. Subsequently, we studied a potential association between the levels of 
inflammatory markers measured during the acute STEMI and abnormal glucose regulation 
classified by an OGTT at three-month follow-up. We found that high levels of CRP and 
MCP-1 measured acutely were associated with abnormal glucose regulation at three-month 
follow-up (adjusted odds ratio 3.2 (95 % CI 1.5, 6.8) and 7.6 (1.7, 34.2)). The association 
between high levels of MCP-1 and abnormal glucose regulation were, however, present only 
in the 150 patients with normal levels of triglycerides (<1.8 mmol/l).   
 
7.4 Paper IV 
A potential association between four selected haemostatic variables measured during the acute 
STEMI and abnormal glucose regulation classified by an OGTT at three-month follow-up 
was investigated. High levels of circulating PAI-1 activity and t-PA antigen measured acutely 
were associated with abnormal glucose regulation classified three months later (adjusted odds 
ratio 2.2 (95 % CI 1.1, 4.4) and 3.5 (1.5, 8.2)). The association between high levels of t-PA 
antigen and abnormal glucose regulation was, however, present only in men. Finally, we 
investigated changes in the levels of haemostatic variables when measured acutely and again 
at three-month follow-up according to glucometabolic state. The levels of all the haemostatic 
variables were lower when measured in a stable condition. There were no significant 
differences in changes in the measured variables from baseline to three-month follow-up 
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between patients with or without abnormal glucose regulation. However, after adjustments for 
infarct size, age and gender the reduction in the levels of prothrombin fragment 1+2 (F1+2) was 
significantly more pronounced in patients with abnormal compared to normal glucose 
regulation (p=0.04).  
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8. Discussion  
8.1 Prevalence of abnormal glucose regulation. 
In paper I, the main approach was to evaluate the reliability of an OGTT-based 
glucometabolic classification performed in-hospital and at three-month follow-up in a STEMI 
population in order to elucidate the prevalence of abnormal glucose regulation and the 
reproducibility of an OGTT.  
The first report on a high incidence of glucosuria in patients with myocardial infarction was 
published in 1922 [79]. Later on it became evident that transient hyperglycaemia was 
common during acute MI [80]. However, the mechanisms for this phenomenon are still 
unclear. Hyperglycaemia may result from a transient stress-induced response or a latent 
impairment in -cell function [81-83]. Furthermore, hyperglycaemia during acute MI has 
been shown to be a risk factor for future cardiovascular events and according to guidelines, 
this potential disturbance should be diagnosed before discharge or early after [31,84]. In the 
Swedish GAMI trial, the prevalence of abnormal glucose regulation at discharge and at three-
month follow-up was 66% (IGT 35% and T2DM 31%) and 65 % (IGT 40% and T2DM 25%), 
respectively [7]. In the present study the prevalence in-hospital and at follow-up was 47% 
(IGR 36 % and T2DM 11%) and 25% (IGR 20% and T2DM 5%), respectively. The 
prevalence in-hospital was in accordance with previous studies [7-9], however, at follow-up 
the prevalence was unexpectedly low and not in line with the above mentioned GAMI trial 
[7]. Very recently a Polish study group reported new prevalence results from a MI population 
comparable to our results [85]. They included patients with acute STEMI without previously 
known diabetes and performed an OGTT before discharge and at three-month follow-up. The 
prevalence of abnormal glucose regulation at discharge and at three-month follow-up was 
48% (IGR 34 % and T2DM 14%) and 29% (IGR 24 % and T2DM 5%), respectively [85] 
(Table 2).  
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In the present study the OGTT was used as a screening tool and the test was performed very 
early after the acute MI, mainly during the first day after admission. The OGTT has been 
criticized regarding the poor reproducibility and the poor validity of a single test. 
Additionally, an OGTT are well known to be time-consuming and burdensome to perform 
[16]. However, a single blood glucose measurement 60 minutes after ingestion of 75 g 
glucose or a standardized OGTT performed the fourth day after acute MI have been shown to 
associate with abnormal glucose regulation three months later [83]. 
The reproducibility of the OGTT is frequently assessed by kappa statistics [86]. In the present 
study the criteria for use of kappa statistics were not met due to two different test situations, 
during acute illness and in a stable condition. As a replacement for kappa statistics the 
observed reproducibility of the OGTT was used [87]. The observed reproducibility was poor, 
only 54 % of the patients were classified into the same glucometabolic state at both occasions. 
This result is in line with similar studies, (Table 2) [18,85,88,89]. Poor reproducibility is 
partly due to the considerable day-to-day within person variability of up to 40 % in blood 
glucose concentrations measured during OGTTs [88]. 
 
Table 2 The prevalence of abnormal glucose regulation (AGR) in hospital and at three-
month, and the observed reproducibility, in three different studies on patients with acute MI. 
 AGR 
Prevalence (%) 
In-hospital 
AGR 
Prevalence (%) 
At three-month  
 
Observed 
reproducibility 
Norhammar A et al. [7] 66 65 49 
Knudsen EC et al. (Paper I)  47 25 54 
Bronisz A et al.[85] 48 29 60 
 
 
The guidelines from 2008 on management of acute MI in patients with persistent ST-segment 
elevation recommend an OGTT to be performed before or early after discharge in patients 
without previously known diabetes [84]. Based on our results, which was confirmed by the 
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polish study, such recommendations might not be advisable in patients with MI. In a 
relatively young patient population with uncomplicated MI it seems reasonable to postpone an 
OGTT screening to clinical follow-up, after the patients have been stabilized.  
 An alternative test in diagnosing glucometabolic disturbances is HbA1c. In the present study, 
HbA1c measured early after an acute STEMI was significantly associated with abnormal 
glucose regulation classified at follow-up. HbA1c measured at admission in patients with 
acute MI without known diabetes has in some studies been shown to associate with newly 
diagnosed diabetes at three-month follow-up [7,90], however, conflicting results exist [85,91]. 
Previously, HbA1c has not been recommended as a diagnostic test for several reasons. A 
standardized method for measuring HbA1c has been lacking. The test is unreliable in patients 
with anaemia or hemoglobinopathies and the existing assays are relatively expensive [16]. 
When the present study was almost finished, an international expert committee with members 
appointed by the ADA, the European Association for the study of Diabetes, and the 
International Diabetes Federation have recommended the use of HbA1c in the diagnosis of 
diabetes [16]. In January 2011, WHO adapted this recommendation [92]. 
8.2 Prognostic aspects. 
In paper II our main findings were that patients with uncomplicated acute STEMI, without 
previously known diabetes, have an excellent long-term prognosis independent of abnormal 
glucose regulation classified either in-hospital or in a stable condition at three-month follow-
up. However, it should be pointed out that five out of six patients, who died during follow-up, 
were classified with abnormal glucose regulation in-hospital. The present results are not in 
line with the similar sized follow-up study of the GAMI trial that found a worse prognosis in 
patients with acute MI and newly diagnosed abnormal glucose tolerance (IGT, T2DM) [31]. 
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However, the GAMI trial is not fully comparable with our study, as demonstrated in Table 3. 
The Swedish patients were older, included a mixed group of patients with NSTEMI and 
STEMI, and only 5 % and 38 % of the patients underwent primary PCI or thrombolysis, 
respectively. Coronary revascularization has been shown to have a positive impact on one-
year prognosis in patients with CAD and diabetes [93]. In the present study 100 % of the 
patients underwent primary PCI and received double anti-platelet treatment. 
 
Table 3 Differences in baseline characteristics between the GAMI trial and the present study.  
 Norhammar et al [7] 
(n=181) 
Knudsen et al (Paper I) 
(n=224) 
Age (years) (mean,SD) 63.5 (9.4) 59 (11.3) 
Male 123 (68%) 185 (83%) 
   
Previous disorder:   
Myocardial infarction  36 (20%) 16 (7%) 
Angina pectoris  60 (33%) 7 (3%) 
Heart failure 14 (8%) 0 
Hypertension (treated)  57 (31%) 58 (26%) 
Hyperlipidaemia (treated) 27 (15%) 20 (9%) 
   
BMI (kg/m2) (mean,SD) 26.6 (4.1) 26.6 (3.4) 
Current smoker 61 (34%) 109 (49%) 
HbA1c at admission (%) (mean,SD) 5.0 (0.6) 5.6 (0.3) 
Blood glucose at admission (mmol/L) (mean,SD) 6.5 (1.4) 7.1 (1.5) 
   
Treatment during hospital stay and at 
discharge
  
Primary PCI 9 (5%) 224 (100%) 
Thrombolysis 68 (38%) 0 
Aspirin   93 % 100% 
Clopidogrel  --- 99% 
-blockers  92% 81% 
Lipid lowering agents   66% 99% 
Angiotensin converting enzyme-inhibitors  14% 16% 
Angiotensin II-receptor blockers --- 8% 
 
 
The follow-up study of the Euro Heart Survey on diabetes and the heart that included a mixed 
population with acute and stable CAD showed that patients with CAD and previously known 
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diabetes had poor prognosis, while patients with newly diagnosed type 2 diabetes were at an 
intermediate risk. Impaired glucose regulation (IFG, IGT) was, however, not identified as an 
independent predictor of poor outcome during one-year follow-up [30]. The follow-up time in 
the Euro Heart Survey on diabetes and the heart might have been too short to demonstrate a 
difference in clinical outcome between patients with normal and impaired glucose regulation. 
In a Japanese study on patients with acute MI, newly detected abnormal glucose tolerance 
(IGT, T2DM) was shown to be a risk factor for future cardiovascular events after five years 
follow-up [94].  
In our patient population only 24 and 10 patients were diagnosed with newly detected 
diabetes in-hospital and at follow-up, respectively. Few patients with newly diagnosed 
diabetes, a relatively young patients population, a majority of first episode of MI and a high 
frequency of patients with one-vessel disease, may explain the excellent prognosis found in 
the present study compared to the results from the follow-up of the GAMI trial and the Euro 
Heart Survey on diabetes and the heart [30,31]. Finally, with a relatively small sample size 
and a limited number of endpoints, we should be cautious with the interpretation of the 
present results. An increased risk of type II errors might have been present.  
  
8.3 Inflammation and abnormal glucose regulation. 
In paper III we showed that elevated levels of MCP-1 and CRP measured in-hospital in our 
patient population were associated with abnormal glucose regulation classified at three-month 
follow-up. Growing evidence support that inflammation plays an important role in 
atherosclerosis and CVD [95]. The levels of CRP have been shown to be elevated in patients 
with STEMI [96,97]. However, there are controversies concerning the stimuli of CRP 
production following revascularized MI. Increased circulating levels have been suggested to 
reflect either the inflammatory response to vascular damage or the systemic inflammatory 
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response to myocardial damage [98]. CRP is produced by the liver as a response to 
stimulation by interleukin-6 (IL-6) that has been suggested to partly be released from the 
ischemic myocardium after MI [99].   
MCP-1 is a chemokine suggested to recruit a proinflammatory subgroup of monocytes to sites 
of atherosclerosis [95]. Patients with an acute MI seem to have a biphasic monocyte response 
with a peak in pro-inflammatory monocytes after 3 days, and a reparative monocytes reaction 
dominating at 5 days [100]. In diabetic patients, circulating MCP-1 levels were shown to 
correlate with HbA1c, BMI, and triglycerides and the serum levels of MCP-1 were 
significantly higher in diabetic than in non-diabetic patients [101]. 
In the present study, the association between levels of CRP and MCP-1 measured in-hospital 
and abnormal glucose regulation classified at follow-up may indicate that impaired beta-cell 
function or transient hyperglycaemia during acute illness may activate the immune system 
during acute STEMI. Experimental hyperglycaemia has been shown to acutely increase the 
concentration of various cytokines (IL-6, tumor necrosis factor-alpha, and interleukin-18 (IL-
18)) in subjects with both normal and impaired glucose tolerance, and the effect was more 
pronounced in the latter [102]. Furthermore, incubation of endothelial cells with CRP 
increased the endothelin-1 production, decreased endothelial nitric oxide release and 
upregulated adhesion molecules and MCP-1 expression [103]. These proatherogenic effects of 
CRP were further potentiated in the presence of hyperglycaemia [103]. In line with this, in 
patients with acute MI, hyperglycaemia was associated with increased levels of inflammatory 
markers such as CRP and IL-18 [104]. In a substudy from the present cohort of STEMI 
patients, we demonstrated that activin A, a member of the transforming growth factor (TGF)-
 superfamily, was significantly associated with abnormal glucose regulation in patients with 
acute MI. Additionally, in vitro findings indicated that this association may represent a 
counteracting mechanism to protect against inflammation, hyperglycaemia, and oxidative 
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stress [105]. All studies taken together, stress-induced hyperglycaemia or hyperglycaemia 
related to impaired -cell function during acute MI, seem to be markers of multiple metabolic 
disorders that may influence the outcome of an acute MI. 
 
8.4 Haemostasis and abnormal glucose regulation. 
In paper IV we demonstrated that elevated levels of PAI-1 activity and t-PA antigen measured 
in-hospital in our study population were significantly associated with abnormal glucose 
regulation classified at three-month follow-up. Additionally, the reduction (from baseline to 
follow-up) in the levels of F1+2 was significantly more pronounced in patients with abnormal 
compared to normal glucose regulation. These results indicate that patients with abnormal 
glucose regulation have a more prothrombotic response during acute STEMI. These results 
are in line with previous studies, which have shown that type 2 diabetes and CAD are known 
prothrombotic conditions due to suppressed fibrinolysis, enhanced coagulation and alterations 
in platelet reactivity [44,55,106,107].  
Suppressed fibrinolysis seems to be associated with type 2 diabetes and CAD mainly due to 
elevated levels of the fibrinolytic inhibitor, PAI-1 [62,108]. The mechanisms that link this 
suppressed fibrinolysis to glucometabolic abnormalities and CAD are, however, unknown 
although in vitro studies have reported that excess insulin may induce PAI-1 expression in 
liver cells [62,109]. Additionally, hyperglycaemia seems to increase PAI-1 expression and 
secretion in endothelial cells and PAI-1 is expressed in adipose tissue [55,110-113]. However, 
these results have not been reproduced in vivo. Hyperinsulinaemia generated during an OGTT 
in patients with CAD, were shown to decrease PAI-1 activity and hyperinsulinaemia during 
glucose clamp showed the same pattern [114-116]. Another study indicates that PAI-1 
secretion probably is dependent on a combination of several metabolic factors [116].  
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Tissue plasminogen activator, the activator of the fibrinolytic system is mainly assessed as t-
PA antigen, reflecting both free t-PA and t-PA in complex with PAI-1 [66]. Elevated levels of 
t-PA antigen have been found in patients with both acute MI and in patients with abnormal 
glucose regulation [106,117]. t-PA antigen are associated with endothelial cell dysfunction 
and is thought to be a robust biomarker of widespread atherosclerosis [118,119]. In our study, 
however, elevated levels of t-PA antigen were probably a measure of elevated PAI-1 activity. 
Furthermore, in the present work the level of F1+2 declined more (from baseline to follow-up) 
in patients with abnormal compared to normal glucose regulation, indicating an elevated 
prothrombotic profile in these patients during acute illness. Markers of thrombin generation 
such as F1+2 and thrombin-anti-thrombin complexes have previously been found to be elevated 
in diabetes [68]. In addition, improved glycemic control in type 2 diabetes has been shown to 
decrease thrombogenecity irrespective of treatment allocation [120]. 
As pointed out in paper III and IV patients classified with abnormal compared to normal 
glucose regulation in a stable condition after STEMI appeared to have an enhanced 
inflammatory and prothrombotic condition during hospitalization. Inflammation in 
combination with transient hyperglycaemia and or hyperinsulinemia in vivo has been shown 
to induce excess coagulation and reduced fibrinolytic activity [73]. Acute stress-induced 
hyperglycaemia, a latent pre-existing disturbance in glucose metabolism accompanied by 
hyperinsulinemia during the acute STEMI or both, may explain the enhanced inflammatory 
and prothrombotic condition found in this patient population. Our findings of a prothrombotic 
condition in patients with abnormal glucose regulation reinforce previous data showing a 
prothrombotic phenotype in patients with diabetes mellitus and insulin resistance. 
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8.5 Limitations 
The recruiting hospital, Oslo University Hospital, Ullevål serves patients from the east 
regions of Norway and stable patients are regularly returned back to the referring hospitals 
within 24-hours after PCI treatment. The short duration of hospitalization limited the ability to 
do a more thorough investigation of glucose regulation during the acute STEMI, including 
repeated OGTTs before hospital discharge.  
Furthermore, according to the described exclusion criteria a selection bias towards more 
glucometabolically normal patients with a low proportion of incident type 2 diabetes, may be 
present. Additionally, at inclusion, all patients were hemodynamically stable without clinical 
signs of heart failure or cardiogenic shock, which may explain the low incidence of new 
events during follow-up. 
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9. Conclusions 
 
The main conclusions from the present work are summarized as follows: 
 The prevalence of abnormal glucose regulation found in our cohort was lower than 
previously reported in patients with acute MI. The prevalence in-hospital was 
relatively high, but half of these patients were classified as having normal glucose 
regulation when re-tested at three-month follow-up. Based on our findings, an early 
OGTT should probably not be recommended, whereas an OGTT performed in a stable 
condition during follow-up in order to identify patients with persistent glucometabolic 
disturbances, seems advisable (Paper I). 
 High levels of HbA1c, admission plasma glucose and fasting plasma glucose (except 
in patients with large MI) measured in-hospital were associated with abnormal glucose 
regulation classified by an OGTT at three-month follow-up, indicating that these 
variables can be used as early markers of a long standing glucometabolic disturbance 
in patients with acute STEMI (Paper I).  
 
 Hemodynamically stable patients with a primary PCI treated STEMI without 
previously known diabetes seem to have an excellent long-term prognosis. 
Additionally, clinical outcome seems to be independent of the presence of newly 
diagnosed abnormal glucose regulation (whether classified in-hospital or at three-
month follow-up) within a three years follow-up period. Any effect of abnormal 
glucose regulation on long-term prognosis (> three years) cannot be interpreted from 
the present work (Paper II). 
 
 Elevated levels of CRP and MCP-1 measured in-hospital in our study population were 
associated with abnormal glucose regulation classified by an OGTT at three-month 
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follow-up, indicating a proinflammatory state during acute STEMI in patients with 
stress induced hyperglycaemia or impaired pancreatic -cell function (Paper III). 
 Elevated levels of PAI-1 activity and t-PA antigen measured in-hospital in the same 
study population were associated with abnormal glucose regulation classified at three-
month follow-up. Furthermore, the decline (from baseline to follow-up) in the levels 
of F1+2, a measure of thrombin generation, was significantly more pronounced in 
patients with abnormal compared to normal glucose regulation. The data indicate an 
enhanced prothrombotic condition during acute STEMI in patients with newly 
detected abnormal glucose regulation (Paper IV). 
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Abstract
Background: A high prevalence of impaired glucose tolerance and unknown type 2-diabetes in
patients with coronary heart disease and no previous diagnosis of diabetes have been reported. The
aims of the present study were to investigate the prevalence of abnormal glucose regulation (AGR)
3 months after an acute ST-elevation myocardial infarction (STEMI) in patients without known
glucometabolic disturbance, to evaluate the reliability of a 75-g oral glucose tolerance test (OGTT)
performed very early after an acute STEMI to predict the presence of AGR at 3 months, and to
study other potential predictors measured in-hospital for AGR at 3 months.
Methods: This was an observational cohort study prospectively enrolling 224 STEMI patients
treated with primary PCI. An OGTT was performed very early after an acute STEMI and was
repeated in 200 patients after 3 months. We summarised the exact agreement observed, and
assessed the observed reproducibility of the OGTTs performed in-hospital and at follow up. The
patients were classified into glucometabolic categories defined according to the World Health
Organisation criteria. AGR was defined as the sum of impaired fasting glucose, impaired glucose
tolerance and type 2-diabetes.
Results: The prevalence of AGR at three months was 24.9% (95% CI 19.1, 31.4%), reduced from
46.9% (95% CI 40.2, 53.6) when measured in-hospital. Only, 108 of 201 (54%) patients remained in
the same glucometabolic category after a repeated OGTT. High levels of HbA1c and admission
plasma glucose in-hospital significantly predicted AGR at 3 months (p < 0.001, p = 0.040,
respectively), and fasting plasma glucose was predictive when patients with large myocardial
infarction were excluded (p < 0.001).
Conclusion: The prevalence of AGR in STEMI patients was lower than expected. HbA1c,
admission plasma glucose and fasting plasma glucose measured in-hospital seem to be useful as early
markers of longstanding glucometabolic disturbance. An OGTT performed very early after a STEMI
did not provide reliable information on long-term glucometabolic state and should probably not be
recommended.
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Background
Several prospective studies have reported a high preva-
lence of impaired glucose tolerance (IGT) and unknown
type 2-diabetes (DM) in patients with coronary heart dis-
ease and no previous diagnosis of DM [1-4] although data
on patients with acute ST-elevation myocardial infarction
are scarce. IGT and DM have been shown to be strong risk
factors for future cardiovascular events after acute myocar-
dial infarction [5]. Recent European guidelines on DM,
prediabetes, and cardiovascular disease recommend that
patients without known diabetes, but with established
cardiovascular disease should be investigated with an oral
glucose tolerance test (OGTT) [6]. However a scientific
statement from the American Heart Association Diabetes
Committee of the Council on Nutrition, Physical Activity,
and Metabolism do not encourage routine use of such
screening [7]. In the European guidelines there is no con-
sensus about the timing of an OGTT performed after an
acute myocardial infarction [6]. Early testing may be con-
founded by stress reactions accompanying an acute myo-
cardial infarction, but could be important in order to
identify patients with cardiovascular events in the first
weeks after an acute myocardial infarction [8]. The Glu-
cose tolerance in Acute Myocardial Infarction (GAMI)
study indicated that an OGTT performed early (day 4–5)
after an acute myocardial infarction [1] provided reliable
information on long-term glucometabolic state [9].
Routine use of OGTT, as stated by the European guide-
lines, in the follow-up of patients with myocardial infarc-
tion has so far not been implemented in Norway. Rapid
transfer of stable patients after primary PCI from tertiary
centers to community hospitals makes it difficult to
implement the new guidelines into daily-life practice. This
study was undertaken to investigate the prevalence of
unknown DM, IGT and impaired fasting glucose (IFG) in
patients with STEMI during stable conditions after 3
months of follow-up and to evaluate the reliability of per-
forming an OGTT-based glucometabolic classification in-
hospital in order to predict glucometabolic disturbance
defined by a repeated OGTT at 3 months. The study had a
practical approach: Performing a very early OGTT at the
PCI center in stable patients, before transfer (usually
within 24 hours) back to community hospitals, in order
to establish screening for unknown DM and IGT in STEMI
patients in our community. Finally, in an explanatory
strategy, to study various biomarkers and risk factors iden-
tified during the initial hospitalisation as possible predic-
tors of DM and IGT defined at 3 months.
Methods
Study population
The study was designed as an observational cohort study
prospectively including STEMI patients treated with pri-
mary PCI admitted to the coronary care unit at Ullevål
University Hospital, Oslo, Norway, between November
2005 and May 2007. The OGTT was performed after over-
night fasting, before transfer from the coronary care unit
back to the referring hospitals. At Ullevål University Hos-
pital, stable patients are regularly returned within 24-
hours after treatment. At enrolment, patients were clini-
cally stable, without persistent glyseroltrinitrat infusion,
chest pain, nausea or symptoms of heart failure. Patients
with known DM, serum creatinine concentration  200
umol/L, and age > 85 years were excluded. The OGTT was
not performed in patients with persistent hyperglycaemia
in order to avoid further glucose overloading.
The Regional ethics committee approved the study and all
patients provided written informed consent. STEMI was
defined as ST-segment elevation of > 2 mm in two or more
contiguous chest leads or > 1 mm in two or more limb
leads or new left bundle-branch block, together with typi-
cal symptoms (chest pain or discomfort > 20 min).
Laboratory methods
Admission plasma glucose concentration was analysed
from a blood sample taken in the catheterisation labora-
tory as soon as possible after PCI. After overnight fasting,
blood samples for routine analysis by use of conventional
methods including plasma glucose, were drawn. A stand-
ardised OGTT (2 h) with 75 g of glucose dissolved in 200
mL water was performed [10]. The median time from bal-
loon to OGTT was 16 hr and 35 min. The OGTT was
repeated after three months.
Serum-cTroponin T was measured by electrochemilumi-
nescence technology for quantitative measurement (3rd
generation cTroponinT, Elecsys 2010, Roche, Mannheim,
Germany). The lower detection limit of the assay is 0.01
ug/l with a recommended diagnostic threshold of 0.03
ug/l. The inter-assay coefficient of variation was 7%.
Urinary albumin excretion was assessed in a morning spot
urine sample and expressed as albumin/creatinine ratio.
Microalbuminuria was defined as 30–300 mg albumin
secreted per 24 hours [11].
Clinical follow-up
At 3 months, the patients underwent an OGTT, clinical
examination, and answered a questionnaire about life-
style changes after discharge from hospital, including
weight, smoking habits, and physical activity. Physical
activity was reported as 30 min of activity, 0–1 days/week,
2–3 days/week, or > 3 days/week.
Single Photon Emission Computed Tomography imaging
Left ventricular ejection fraction, end-diastolic and end-
systolic volume and infarct size expressed as percent of left
ventricular mass, were assessed at rest after 3 months by
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Single Photon Emission Computed Tomography imaging
with technetium 99 m-tetrofosmin [12].
Classification of glucometabolic state
The different glucometabolic categories were defined
according to the World Organisation criteria [13]. Classi-
fication of glucometabolic state was primarily based on
the result of an OGTT and the patients were divided into
one of the following four categories, (glucose levels given
in mmol/l):
Normal Glucose Regulation (NGR) = OGTT (0 min) < 6.1
and OGTT (2 h) < 7.8
Impaired Fasting Glucose (IFG) = OGTT (0 min)  6.1 <
7.0 and OGTT (2 h) < 7.8
Impaired Glucose Tolerance (IGT) = OGTT (0 min) < 7.0
and OGTT (2 h)  7.8 < 11.1
Type 2-diabetes (DM) = OGTT (0 min)  7.0 and/or OGTT
(2 h)  11.1
Because of limited number in each category, the patients
were also divided into:
Abnormal Glucose Regulation (AGR) = IFG+IGT+DM or
NGR.
The patients were also categorised based on the results of
fasting plasma glucose (FPG) only:
Normal Glucose Regulation (NGR) = FPG < 6.1
Impaired Fasting Glucose (IFG) = FPG  6.1 < 7.0
Type 2-diabetes (DM) = FPG  7.0
Statistics
In the prevalence study an apriori power analysis was per-
formed. With a hypothesised prevalence of AGR of 60%
[1-3] with a precision of 5% and a chosen probability of
90% a sample size of 222 patients was needed to deter-
mine the prevalence of unknown AGR. Furthermore, a
post hoc power analysis was done for potential in-hospi-
tal predictors for the outcome AGR at 3 months showing
that 116 patients were required considering a type 1-error
of 5%, a power of 80%, a prevalence of AGR in patients
with low HbA1c of 17%, and an OR (crude) = 4.15 for the
association HbA1c on AGR. Similar analyses were also
performed with the associations of fasting plasma glucose
and admission plasma glucose on AGR.
Values are presented as median (25, 75% quartiles) or
proportions. Mann-Whitney's test was used for comparing
groups. In order to identify possible in-hospital predictors
of AGR defined at 3 months, we hypothesised an associa-
tion between the 3 exposition variables HbA1c, fasting
plasma glucose, and admission plasma glucose and the
outcome AGR. The other variables were potential con-
founders or effect modifiers of this association. The odds
ratio (OR) and its 95% confidence interval (CI) were used
to quantify this association. We performed a stratification
analysis and dichotomised continuous exposition varia-
bles into high and low values using the cut-off point 6.1
mmol/l for fasting plasma glucose according to the litera-
ture and the 75% percentile in the present material for the
other variables. The Mantel-Haenszel method was used to
highlight potential effect modification by the Breslow-
Day test of heterogeneity and to quantify potential con-
founders [14]. Additional information is available online
(see additional file 1).
A logistic regression model, including a backward elimi-
nation procedure and finally taking in consideration the
concept of validity and precisions, performed adjustment
for multi-confounders. The STROBE guidelines were fol-
lowed [15].
Analyses were performed using Epi-info software, 2005,
version 3.3.2.
A value of p < 0.05 was considered statistically significant.
Results
Baseline and follow up characteristics
Two hundred and twenty five patients without previously
known DM or IGT were enrolled in the study. The OGTT
was well tolerated, 224 completed an in-hospital OGTT
while one patient interrupted the test because of acute
nausea. None of the patients complained of chest-pain or
underwent a new coronary angiography. No in-hospital
deaths occurred. The median time from onset of chest
pain to balloon (PCI) was 3 hr and 39 min and 16 hr and
35 min from balloon to OGTT. The OGTT was repeated in
200 patients after 3 months. The reasons for not repeating
the test were: death (n = 1), fasting plasma glucose > 7.0
mmol/L (n = 1) and unwillingness (n = 22). Table 1 sum-
marises the baseline characteristics of the study popula-
tion. Notably, the majority of the patients presented with
their first myocardial infarction, 62% had single vessel
disease and 92% of the patients were in Killip class 1 (data
not shown). Single photon emission computed tomogra-
phy imaging at 3 months showed that 85% of the patients
had an left ventricular ejection fraction > 50%.
At 3 months 25% of the patients had stopped smoking,
41% had increased the number of days per week of phys-
ical activity, 36% had lost weight and 30% had gained
weight. The proportion of AGR in patients who had lost
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weight and in patients who had gained weight was 28%
and 25%, respectively (data not shown).
Prevalence of AGR
The median plasma glucose concentration at admission
was 6.9 mmol/L ((25, 75% percentiles) 6.0, 7.8), the
median fasting plasma glucose was 5.3 mmol/L (4.9, 5.9)
and the median HbA1c value was 5.5% (5.3, 5.8) (n =
207). Figure 1 shows the prevalence of NGR, IFG, IGT and
DM in-hospital and at 3 months, based on a glucometa-
bolic classification by OGTT and alternatively, by fasting
plasma glucose alone. Based on the given categories we
defined, abnormal glucose regulation (AGR) as the sum of
IFG, IGT and DM, in spite of different risk profiles
between IFG, IGT and DM. The prevalence of AGR after an
OGTT- based classification was 46.9% (95% CI 40.4,
53.9) (n = 224) in-hospital and 24.9% (19.1, 31.4) (n =
201) at 3 months, respectively.
Table 2 compares the results of an OGTT- based glucomet-
abolic classification of the patients in-hospital and at 3
months. Fifty-four % of the patients remained in the same
glucometabolic category after a repeated OGTT. Only 5
out of 22 patients defined as diabetic in-hospital
remained in the diabetic category after 3 months.
Predictors of AGR
In Table 3, patient characteristics assessed at hospitalisa-
tion are compared between the NGR group and the AGR
group, as defined by an OGTT three months later. Patients
with AGR were older, there were significantly more
women, and they had significantly higher levels of
HbA1c, admission plasma glucose, and fasting plasma
glucose.
In univariate analyses HbA1c, admission plasma glucose
and fasting plasma glucose significantly predicted the
presence of AGR at 3 months (p < 0.001, p = 0.006 and p
= 0.011, respectively) (Table 4). HbA1c (p < 0.001) and
admission plasma glucose (p = 0.040), analysed sepa-
rately, remained significantly predictive after adjustment
for confounders (Table 4). When analysing on fasting
plasma glucose concentration as an independent biomar-
ker, serum-cTroponinT modified the effect of fasting
plasma glucose on AGR, thus the results were stratified
into two subgroups, and as shown in Table 4, fasting
plasma glucose was independently predicting AGR at 3
months only in patients with serum-cTroponin T below
the highest quartile (< 8.80 ug/l), with an adjusted OR
5.50 (95% CI 2.00, 15.10).
Discussion
Prevalence of AGR
The main findings in the present study were that only 25%
of the patients were classified by OGTT as having AGR in
a clinically steady situation 3 months after an acute STEMI
and only about 5% had previously unknown DM. About
50% of the patients with STEMI were classified as having
undetected AGR based on an OGTT classification in-hos-
pital, but only half of these patients remained in the AGR
group after a repeated OGTT 3 months later. Using fasting
plasma glucose classification only, about 50% of the
patients with AGR would have been misclassified, both
in-hospital and after 3 months. To disclose the actual glu-
cometabolic state in these patients it seems necessary to
perform an OGTT. The latter result is in line with a previ-
ous study, showing that two-thirds of the patients with
undiagnosed diabetes would have been missed using fast-
ing plasma glucose classification alone [2].
In the present study the OGTT was performed very early
after a PCI treated STEMI and an initially higher preva-
lence of AGR could be expected as an acute STEMI is
accompanied by a substantial release of stress hormones.
However, we found a somewhat lower prevalence of AGR
than reported in previous studies, both in-hospital and at
3 months. Three prospective studies on mixed popula-
tions of patients with acute and stable coronary artery dis-
Table 1: Baseline characteristics of the total population (n = 
224)
Patients
Age (years) 58 (51, 67)
Male 185 (82.6%)
Previous disorder:
Myocardial infarction 16 (7.1%)
Angina pectoris 7 (3.1%)
Hypertension (treated) 58 (25.9%)
Hyperlipidaemia (treated) 20 (8.9%)
Status at baseline
Current smoker 109 (48.7%)
BMI (kg/m2) 26 (24.4, 28.7)
Waist circumference (cm) 100 (94, 107)
Stent in culprit lesion 215 (96.0%)
Gp IIb/IIIa antagonist treated 79 (35.3%)
Single -coronary vessel disease 139 (62.1%)
Double-coronary vessel disease 64 (28.6%)
Triple-coronary vessel disease 21 (9.4%)
Time from symptoms to balloon (min) 219 (140, 378)
Time from PCI to OGTT (min) 995 (689, 1277)
Medication at discharge from CCU
Aspirin 224 (100%)
Clopidogrel 222 (99.1%)
-blockers 181 (80.8%)
Lipid lowering agents 221 (98.7%)
Angiotensin converting enzyme-inhibitors 36 (16.1%)
Angiotensin II-receptor blockers 18 (8.0%)
LVEFa 64 (56, 70)
Data are presented as median with inter-quartile range or 
proportions.
BMI: body mass index, LVEF: left ventricular ejection fraction. aLVEF 
diagnosed 3 months after discharge.
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ease have shown that about 60% of the patients had
undiagnosed AGR [1-3]. A repeated OGTT was performed
only in one of these studies showing that 66% of the
patients had AGR before hospital discharge [1] and the
prevalence was reported to be similar after 3 and 12
months [9]. In the present study the prevalence of AGR at
3 months was much lower, which the selected population
of STEMI patients may partly explain. The patients were
mainly Caucasians, relatively young, included a low
number of women, a high proportion of first acute myo-
cardial infarction, and a preponderance of single vessel
disease. Additionally, patients with persistent hypergly-
caemia were excluded. It is possible that the prevalence of
AGR after 3 months would have been higher if these
patients had been included in the 3 months follow-up.
The prevalence of AGR was reduced by about 50% after 3
months indicating poor reliability of the early classifica-
Glucometabolic classification of 201 STEMI patients based on the results of an OGTT or fasting plasma glucose only, in-hospital and at 3 monthsFigure 1
Glucometabolic classification of 201 STEMI patients based on the results of an OGTT or fasting plasma glu-
cose only, in-hospital and at 3 months. FPG: fasting plasma glucose, IFG: impaired fasting glucose, IGT: impaired glucose 
tolerance, NGR: normal glucose regulation, OGTT: oral glucose tolerance test, DM: type 2-diabetes.
Table 2: Glucometabolic classification by OGTT in patients with ST-elevation infarction in-hospital (OGTT1, row), and at 3 months 
(OGTT2, column)
NGR (OGTT2) IFG (OGTT2) IGT (OGTT2) DM (OGTT2) Total (OGTT1)
NGR (OGTT1) 91 6 11 1 109
IFG (OGTT1) 8 1 1 0 10
IGT (OGTT1) 41 4 11 4 60
DM (OGTT1) 11 0 6 5 22
Total (OGTT2) 151 11 29 10 201
Data are number of patients.
Observed concordance: 53.7%
One patient was categorized based on the results of fasting plasma glucose only, because of persistent hyperglycaemia.
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tion. The measured in-hospital prevalence of AGR reflects
not only long-standing glucometabolic disturbance, but
also an acute stress epiphenomenon as discussed.
OGTT in patients with STEMI
Patients with acute myocardial infarction and diabetes
have a higher short and long-term mortality rate than
non-diabetic patients [16]. The 2-hour blood glucose has
been shown to be superior to fasting blood glucose to pre-
dict the risk of future cardiovascular disease and death
from all causes in individuals with hyperglycaemia [17].
The present study revealed that a very early OGTT in
STEMI-patients was well tolerated, except in one patient.
None of the patients died in-hospital, reflecting the inten-
tion to exclude unstable patients.
To examine the reproducibility of an OGTT, two inde-
pendent tests should be performed within a short period
of time in stable patients without persistent acute ill-
ness[10]. Even under these circumstances previous studies
have suggested poor reproducibility of an OGTT [18]. In
the present study we compared the OGTT performed after
initial stabilisation of acute illness, and stable disease,
thus we did not test the reproducibility of the OGTT, but
evaluated the reliability of an early glucometabolic classi-
fication by OGTT by repeating the test after 3 months.
Generally, the variation in the repeated OGTT results has
to a great extent been explained by the random variation
of plasma glucose concentration [19]. In our study the
variation in the OGTT results after 3 months of follow up
to a great extent may have been influenced by the different
test situation mentioned. This is in line with another
Table 3: Clinical and laboratory characteristics of patients in-hospital according to glucometabolic category defined by OGTT at 3 
months
NGR (n = 151) AGR (n = 50) P
Age (years) 57 (51, 65) 61 (52, 72) 0.037
Male 129 (85.4%) 36 (72.0%) 0.032
Current smoker 67 (44.4%) 24 (48.0%) 0.656
Treated hypertension 38 (25.2%) 17 (34.0%) 0.226
BMI (kg/m2) 26.2 (24.3, 28.7) 26.1 (24.6, 28.7) 0.741
Cholesterol (mmol/l) 5.1 (4.4, 5.7) 5.1 (4.4, 5.7) 0.839
Triglycerides (mmol/l) 1.27(0.89, 1.79) 1.25 (0.96, 1.83) 0.623
HDL-cholesterol (mmol/l) 1.19 (0.97, 1.43) 1.12 (1.00, 1.35) 0.659
Serum uric acid (mmol/l) 334 (289, 382) 347 (282, 409) 0.288
Microalbuminuria 26 (18.2%) 10 (22.2%) 0.549
scTnT (ug/l) 4.85 (2.45, 8.31) 4.97 (2.38, 10.25) 0.469
HbA1c (%) 5.5 (5.3, 5.7) 5.8 (5.5, 6.0) < 0.001
Admission plasma glucose (mmol/l) 6.6 (5.8, 7.5) 7.4 (6.6, 8.7) <0.001
FPG (mmol/l) 5.2 (4.9, 5.7) 5.6 (5.1, 6.3) 0.003
Data are presented as median with inter-quartile range or proportions.
AGR: abnormal glucose regulation, BMI: body-mass index, FPG: fasting plasma glucose, NGR: normal glucose regulation, scTnT: serum-cTroponinT.
Table 4: Logistic regression analysis of HbA1c, admission plasma glucose and fasting plasma glucose as independent predictors in-
hospital for AGR defined by an OGTT at 3 months
AGR AGR AGR
scTnT > 8.80 ug/l
(n = 51)
AGR
scTnT < 8.80 ug/l
(n = 150)
OR (crude)
(95% CI)
P OR (adjusted)
(95% CI)
P OR (adjusted)
(95% CI)
P OR (adjusted)
(95% CI)
P
HbA1ca
> 5.7%
4.15
(2.03, 8.48)
<0.001 3.76
(1.82, 7.79)
<0.001
Admission plasma glucoseb
> 7.7 mmol/l
2.59
(1.31, 5.12)
0.006 2.12
(1.03, 4.33)
0.040
FPG c
 6.1 mmol/L
2.62
(1.25, 5.50)
0.011 0.69
(0.15, 3.14)
0.636 5.50
(2.00, 15.10)
<0.001
AGR: abnormal glucose regulation, FPG: fasting plasma glucose, scTnT: serum-cTroponinT.
aAdjusted for gender and age.
bAdjusted for age.
cscTnT > 8.80 ug/l (highest quartile) was an effect modifier on the association FPG on AGR, thus data are presented in 2 subgroups, both adjusted 
for age, uric acid and gender.
Cardiovascular Diabetology 2009, 8:6 http://www.cardiab.com/content/8/1/6
Page 7 of 8
(page number not for citation purposes)
study showing that acute myocardial infarction induces
hyperglycaemia and give rice to insulin resistance [20].
These investigators demonstrated that blood glucose lev-
els and HOMA-IR decreased significantly during hospital
stay with no further decrease between discharge (day 4–5)
and 3 months of follow up reflecting that acute illness
influence the very early rise and fall in glucose levels in-
hospital [20].
Only 54% of the patients in our study were classified into
the same glucometabolic state on both occasions which is
in accordance with results from other studies performing
repeated OGTTs [20,21]. The intra-individual tracking of
oral glucose tolerance in our study was poor, but compa-
rable to what was found in the GAMI study (49 and 54%,
respectively) [20]. In the present study, 11 out of 22
patients classified as having diabetes in-hospital con-
verted to NGR at 3 months. These results underline the
World Health Organisation recommendation for a
repeated OGTT under stable conditions to confirm or
exclude an abnormality of glucose regulation in asympto-
matic individuals [10]. Nevertheless, individuals with one
abnormal OGTT have been shown to have a higher cardi-
ovascular risk profile compared to individuals who had
two normal OGTTs [18] and a single positive OGTT in
patients with acute myocardial infarction seems to iden-
tify patients at higher risk of future cardiovascular event
[5]. The present study do not address whether an early
OGTT after a myocardial infarction can identify patients
with worse prognosis.
Predictors of AGR
In order to identify patients with AGR after 3 months
without performing an in-hospital OGTT, analysis of risk
markers was undertaken. We could not demonstrate any
differences in baseline values of conventional cardiovas-
cular disease risk factors between the AGR and NGR
groups, classified after 3 months. However, a high HbA1c
value and a high admission plasma glucose value in-hos-
pital were independently predicting AGR at 3 months
with an adjusted OR of 3.76 and 2.12, respectively. Fur-
thermore, a high fasting plasma glucose value in-hospital,
strongly predicted AGR at 3 months (adjusted OR 5.50),
when patients with large myocardial infarction were
excluded indicating that an acute stress reaction may
dominate in patients with a large acute myocardial infarc-
tion.
This is in accordance with other studies showing HbA1c
values at admission and fasting plasma glucose at dis-
charge from hospital (day 4 after acute myocardial infarc-
tion) to be independent predictors of AGR at 3 months
[1].
Clinical implication
The European guidelines recommend that patients with-
out known diabetes, but with established cardiovascular
disease should be investigated with an OGTT [6]. In order
to try to implement the new guidelines in our region we
performed an OGTT before transfer to referring hospitals.
The present results demonstrate that it is safe to perform a
very early OGTT in stable patients with acute STEMI, but
a very early classification did not provide reliable informa-
tion on long-term glucometabolic state, and the present
results do not encourage routine use of an OGTT at this
early time point in acute STEMI patients However, a sub-
stantial proportion of the patients had undetected AGR
after 3 months and it is important to diagnose these
patients and offer them a close follow- up on lifestyle
interventions and optimal medical treatment in order to
reduce events in this high-risk population.
Limitations
Unstable patients and patients with persistent hypergly-
caemia in-hospital were excluded from the study to avoid
further glucose loading, possibly making a selection bias
towards more glucometabolically normal patients. This
may have contributed to the somewhat unexpected low
prevalence of undetected AGR in STEMI patients.
Conclusion
The prevalence of AGR in a STEMI-population was lower
than previously reported in patients with acute myocar-
dial infarction. The prevalence was relatively high when
measured in-hospital by a very early OGTT, but half of
these patients were categorised as having normal glucose
regulation when re-tested at 3 months. Based on these
results an OGTT should probably not be recommended
very early after an acute STEMI whereas an OGTT should
be performed during follow-up in order to identify
patients with persistent glucometabolic disturbances.
High levels of HbA1c, admission plasma glucose and fast-
ing plasma glucose (except in patients with large myocar-
dial infarction) measured in-hospital predicted an
increased risk of AGR defined at 3 months, indicating that
these biomarkers can be used as early markers of a long
standing glucometabolic disturbance in patients with
acute myocardial infarction.
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Table A. Stratified analysis on the association between the 3 exposition variables HbA1c, 
fasting plasma glucose, and admission plasma glucose and the outcome abnormal glucose 
regulation on major potential confounders using the Mantel-Haenzel (MH) method.     
                        AGR-      AGR+            odds ratio             odds ratio MH         Breslow &Day  
                                                               (95%CI)               (95%CI)               Heterogeneity test   
                      HbA1c        HbA1c                                                                         p-value 
                           (< 5.8 % ) 
                      no   yes       no   yes 
Age 
  67 year           93  19        15   13        4.24 (1.74-10.35)    3.72 (1.80-7.70)        0.6476 
>67                  19    8          8   10        2.97 (0.86-10.30) 
Gender 
  Male              98  21         17  17        4.67 (2.05-10.61)    3.91 (1.90-8.02)        0.4225       
 Female            14   6           6    6         2.33 (0.53-10.27) 
Crude effect   112  27        23   23       4.15 (2.03-8.48) 
                       Fasting plasma glucose.  
                         (< 6.1 mmol/L ) 
                        no  yes        no  yes 
Age 
  67 year         104   16       18  12       4.33 (1.76-10.66)      2.48 (1.18-5.20)          0.0541 
>67                  24    7        16    4       0.86 (0.22-3.41)                                
Gender 
 Male             111   18       25   11       2.71 (1.14-6.45)       2.45 (1.16-5.20)          0.6789 
Female             17    5         9     5       1.89 (0.43-8.30) 
scTnT 
 <8.80 ug/l    105   12       22   11       4.38 (1.71, 11.18)     *                                  0.0448 
 >8.80             23   11       12     5       0.87 (0.25, 3.09) 
High uric acid  
<387 umol/l     97  20        21  12       2.77 (1.18-6.53)       2.86 (1.34-6.10)          0.8838 
>387                31   3         13    4       3.18 (0.62-16.24)       
Crude effect  128   23        34   16      2.62 (1.25-5.50) 
                    Admission plasma glucose. 
                       (< 7.8 mmol/L )  
                     no  yes          no  yes 
Gender        
 Male             105 24         21  15        3.13 (1.41-6.94)        2.32 (1.17-4.60)          0.1872   
 Female           13   9            8   6        1.08 (0.28-4.21) 
Age 
  67 year         101 19         20  10         2.66 (1.08-6.56)       2.08 (1.02-4.23)          0.4298 
>67                  17 14           9  11        1.48 (0.48-4.59)  
Current smoker 
 No                  61  23        13   13        2.65 (1.07-6.56)       2.73 (1.36-5.47)          0.9204 
 Yes                 57  10        16     8        2.85 (0.97-8.41) 
High LDL-cholesterol 
<4.12 mmol/l   90  20        25   15        2.70 (1.21-6.03) 
>4.12               28  13          4     6        3.23( 0.78-13.45)    2.82 (1.40-5.68)           0.8298       
 
Crude effect   118  33         29  21        2.59 (1.31-5.12) 
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*Cannot be calculated because serum-cTroponinT (scTnT) is an effect modifier of fasting 
plasma glucose on abnormal glucose regulation (AGR). 
The confounding effect is quantified using the formula; 
 odds ratioMH - odds ratiocrude / odds ratiocrude 
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Abstract
Background: Patients with acute myocardial infarction and newly detected abnormal glucose 
regulation have been shown to have a less favourable prognosis compared to patients with 
normal glucose regulation. The importance and timing of oral glucose tolerance testing 
(OGTT) in patients with acute myocardial infarction without known diabetes is uncertain. The 
aim of the present study was to evaluate the impact of abnormal glucose regulation classified 
by an OGTT in-hospital and at three-month follow-up on clinical outcome in patients with 
acute ST elevation myocardial infarction (STEMI) without known diabetes. 
Methods: Patients (n=224, age 58 years) with a primary percutanous coronary intervention 
(PCI) treated STEMI were followed for clinical events (all-cause mortality, non-fatal 
myocardial re-infarction, recurrent ischemia causing hospital admission, and stroke). The 
patients were classified by a standardised 75 g OGTT at two time points, first, at a median 
time of 16.5 hours after hospital admission, then at three-month follow-up. Based on the 
OGTT results, the patients were categorised according to the WHO criteria and the term 
abnormal glucose regulation was defined as the sum of impaired fasting glucose, impaired 
glucose tolerance and type 2-diabetes.  
Results: The number of patients diagnosed with abnormal glucose regulation in-hospital and 
at three-month was 105 (47 %) and 50 (25 %), respectively. During the follow up time of 
(median) 33 (27, 39) months, 58 (25.9%) patients experienced a new clinical event. There 
were six deaths, 15 non-fatal re-infarction, 33 recurrent ischemia, and four strokes. Kaplan-
Meier analysis of survival free of composite end-points showed similar results in patients with 
abnormal and normal glucose regulation, both when classified in-hospital (p=0.4) and re-
classified three months later (p=0.3).  
Conclusions: Patients with a primary PCI treated STEMI, without previously known 
diabetes, appear to have an excellent long-term prognosis, independent of the glucometabolic 
state classified by an OGTT in-hospital or at three-month follow-up.  
 
Trial registration: The trial is registered at www.clinicaltrials.gov, NCT00926133. 
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Background
Patients hospitalised with acute myocardial infarction (MI) have a reported incidence of 
known type 2 diabetes between 10 and 20 % [1]. Patients with type 2 diabetes and acute MI 
have a higher incidence of new cardiovascular events and higher in-hospital and long-term 
mortality rate compared to non-diabetic patients [2-4]. In diabetic patients with ST elevation 
myocardial infarction (STEMI), primary percutaneous coronary intervention (PCI) with 
adjunctive glycoprotein IIb/IIIa inhibition has been shown to be associated with improved 
prognosis compared to fibrinolytic treatment [5]. 
Several studies have reported that a substantial proportion of patients with acute MI, without 
known type 2 diabetes, have disturbed glucometabolic regulation [6,7]. In addition, an 
increased risk of cardiovascular morbidity and mortality has been demonstrated in patients 
with acute MI and newly detected abnormal glucose regulation [8], emphasizing the 
importance of diagnosing these patients at an early stage. Accordingly, the European 
guidelines on diabetes, pre-diabetes and cardiovascular diseases from 2007 recommend that 
these patients should be investigated with an oral glucose tolerance test (OGTT) [9]. The 
timing and importance of broad OGTT screening after an acute MI are, however uncertain, 
especially in patients subjected to modern treatment with primary PCI resulting in smaller 
infarct size and improved prognosis.  
We have previously reported that patients with a primary PCI treated STEMI without known 
diabetes, have a high prevalence of undetected abnormal glucose regulation classified by an 
OGTT either in-hospital or three months later [10]. However, when repeating an OGTT in a 
stable condition at three-month follow-up the observed reproducibility of the early test was 
poor, only 54 % of the patients remained in the same glucometabolic category after a repeated 
OGTT. The OGTT performed early after a STEMI did not provide reliable information on 
long-term glucometabolic state [10].  
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An additional rationale for an early OGTT in patients without known diabetes with a recent 
acute MI is to identify high-risk patients with poor prognosis. The aim of the present study 
was to investigate clinical outcome in patients with a primary PCI treated STEMI after 
exclusion of patients with known diabetes. Secondly, to evaluate whether abnormal glucose 
regulation classified by OGTT acutely in-hospital or in a stable condition at three-month 
follow-up was associated with poorer long-term prognosis after acute STEMI.  
 
Methods
Study population 
Patients with an acute STEMI without known diabetes admitted to the coronary care unit, 
Oslo University Hospital, Ullevål, Oslo, Norway were prospectively enrolled from November 
2005 to May 2007. The cohort is described in detail elsewhere [10]. In brief, patients with a 
primary PCI treated STEMI were included if they were hemodynamically stable, without 
chest pain or nausea, age < 85 years and with serum creatinine < 200 umol/L. Patients with 
previously known type 2 diabetes, persistent hyperglycaemia or clinical signs of heart failure 
were excluded. Heart failure complicating acute MI was defined according to the ESC 
Guidelines from 2008 [11]. Patients with persistent hyperglycaemia were defined as patients 
with both admission plasma glucose >11 mmol/L and a fasting capillary glucose level > 8 
mmol/L. A standardized 75 g OGTT (plasma glucose measurements at 0 and 120 min) was 
performed after an overnight fast [12]. Altogether 224 patients were included. The inclusion 
date was defined as the date when the primary PCI was performed. 
Based on the result of the OGTT, the patients were glucometabolically classified according to 
the WHO guidelines from 2005 into one of the following categories [13] (glucose levels given 
in mmol/L):  
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Normal Glucose Tolerance (NGT) = OGTT (0 min) < 6.1 and OGTT (2 h) < 7.8 
Impaired Fasting Glucose (IFG) = OGTT (0 min)  6.1  < 7.0 and OGTT (2 h) < 7.8 
Impaired Glucose Tolerance (IGT) = OGTT (0 min) < 7.0 and OGTT (2 h) 7.8 < 11.1 
Type 2 diabetes (T2DM) = OGTT (0 min) 7.0 and / or OGTT (2 h) 11.1. 
 
The term abnormal glucose regulation was defined as the sum of IFG, IGT and T2DM.   
This was an observational study. The results of analyses of blood glucose, either fasting or 
during OGTT were available for the treating physician at all time. Hyperglycaemia, if present, 
was treated at the physician’s decision according to local, hospital practice. Patients were 
returned back to the referring hospital with a hospital record, which included information 
about the OGTT results. The responsible physician was asked to perform plasma glucose 
analyses repeatedly and start treatment if indicated. A diagnosis of diabetes was not based on 
the early OGTT performed during acute illness. The results of the OGTT and fasting glucose 
value were communicated to the general practitioners (GP) responsible for the patient. If an 
asymptomatic patient were diagnosed with type 2 diabetes at both occasions (in-hospital and 
at follow-up) the GP was contacted by phone and asked to confirm the diagnosis and initiate 
lifestyle changes and medical treatment according to national guidelines.  
STEMI was defined according to the universal definition of myocardial infarction as typical 
rise and fall of the cardiac biomarker troponin T with at least one value above the 99th 
percentile of the upper reference limit in patients presenting with symptoms of ischemia 
together with new ST elevation at the J-point in two contiguous leads with the cut-off points: 
0.2 mV in men or 0.15 mV in women in leads V2–V3 and/or 0.1 mV in other leads or new 
left bundle-branch block [14]. The median time from onset of chest pain to balloon (PCI) was 
219 minutes (140, 378). 
The Regional ethics committee approved the study and all patients provided written and oral 
informed consent.  
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 Laboratory methods 
After overnight fasting, blood samples for routine analysis including glucose and HbA1c were 
drawn and analysed by use of conventional methods. Serum cardiac specific Troponin T 
(TnT) was measured by electrochemiluminescence technology for quantitative measurement 
(3rd generation TnT, Elecsys 2010, Roche, Mannheim, Germany). The lower detection limit of 
the assay is 0.01 ug/L with a recommended diagnostic threshold of 0.03 ug/L. The inter-assay 
coefficient of variation was 7 %. 
Insulin was measured by a competitive radioimmunoassay (RIA) kit (Linco Research, Inc, 
ST. Charles, MO, US) and C-peptide was determined by Immulite 2000 (Diagnostic Product 
Corporation, Los Angeles, CA, US). Proinsulin was measured by an enzyme immunoassay 
(kit) from DRG instruments (Gmbtt, Marburg. Germany). The homeostasis model assessment 
of insulin resistance (HOMA-IR) was calculated as fasting serum insulin (in pmol/L) 
multiplied with fasting plasma glucose (in mmol/L) and divided by 135 [15].  
 
 Follow up 
At three-month follow-up, clinical examination and a repeated OGTT were performed. 
In addition, left-ventricular (LV) function and infarct size were assessed at rest at follow-up. 
Perfusion imaging was performed according to ECG-gated SPECT after injection of 99m-
tetrofosmin (Myoview™, Amersham Health, UK). An Exeleris processing station (GE 
Medical Systems) with 4D-MSPECT™ software (University of Michigan), was used for 
processing of all recordings and assessment LV volumes, LV ejection fraction (LVEF) and 
infarct size (proportion perfusion defect) expressed as percent of LV mass [16].  
In June 2009, at a median follow up time of 33 months, the patients were contacted and 
interviewed by telephone, regarding their health status, and any hospital admissions. Closing 
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date was set to August 1st 2009. None of the patients were lost to long-term follow-up, but 
only 201 patients attended the three-month follow-up examination. In case of re-
hospitalisation, hospital records were collected from the patients’ community hospitals.  
The primary endpoint of the study was defined as the composite of the first event of non-fatal 
myocardial re-infarction, recurrent ischemia causing hospital admission, stroke, and all cause 
mortality. An end-point committee classified the end-points according to the hospital records, 
and death certificates were obtained from the Norwegian Death Certificate Registry.  
 
Statistics
Continuous variables are presented as median and 25, 75 percentiles and categorical variables 
as proportions. Due to skewness in most of the measured variables, non-parametric statistics 
was used throughout.  Differences among groups were analysed by Mann-Whitney test for 
continuous variables and the Chi square test for categorical data.  
Univariate and multivariate analyses of this dynamic cohort with censored data (Kaplan–
Meier survival, Log-Rank test and Cox proportional hazard models) were performed. 
Potential confounders that were associated with clinical outcome or abnormal glucose 
regulation with a p-value <0.2, were included in the model. The following risk factors were 
included in a stratification model; age, gender, treated hypertension at admission, previous 
myocardial infarction, smoking, body mass index, elevated triglycerides and cholesterol, 
TnTmax, and infarct size expressed as percent of ventricular mass. Adjustment for the 
potential confounders identified by the model was performed [17] and the follow-up time in 
patients years was included. The STROBE guidelines were followed [18]. 
A two-sided p value <0.05 was considered statistically significant. All analyses were 
performed using Epi-info software, 2005, version 3.3.2.  
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Results
In-hospital OGTT was successfully performed in all patients (n=224) and categorised as 
described. As previously reported [10], the prevalence of abnormal glucose regulation in-
hospital was 47 % (n=105), of whom 24 patients (23 %) (or 11 % of the total population, 
n=224) were classified with newly detected type 2 diabetes.  
 
The OGTT was repeated in 201 patients three months after the acute STEMI. Twenty-three 
patients did not perform the repeated OGTT due to death (n=1) or unwillingness (n=22). The 
22 patients who were unwilling to participate at three-month follow-up did, however, take 
part in the interview by telephone in June 2009. Five out of 22 patients reported a new clinical 
event during follow-up, one patient within the first three months, and four patients between 
three-months and (median time) 33 months follow-up. The number of patients with normal 
and abnormal glucose regulation classified in-hospital was 9 and 13, respectively, and two out 
of five with a new clinical event had abnormal glucose regulation. The prevalence of 
abnormal glucose regulation in the total population at three-month follow-up was reduced to 
25 % (n=50), of whom 10 patients (20 %) (or 5 % of the total population, n=201) were 
classified as having type 2 diabetes [10].  
 
Clinical and biochemical characteristics 
Clinical characteristics of the study population according to the glucometabolic classification 
in-hospital and at three-month follow-up are shown in Table 1. Notably, patients with 
abnormal compared to normal glucose regulation were older, a higher proportion were 
women, and they had larger myocardial infarct size measured as % of left ventricular mass 
three months later. Significantly higher levels of HbA1c, insulin, proinsulin, and HOMA-IR 
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(measured in-hospital and at three-month follow-up) were found in patients with newly 
detected abnormal glucose regulation independently of the classification time point (Table 2).  
When comparing patients with and without new clinical events, there were no significant 
differences in clinical or biochemical characteristics (data not shown). 
Glucose lowering medication was not introduced in-hospital or during the three-month 
follow-up period in any of the patients.  
 
Follow-up 
The median follow-up time for clinical events was 33 months (27, 39). The long-term clinical 
outcome was excellent with low event-rate. Of the total population (n=224), 58 (26%) 
patients experienced a new clinical event including 33 patients with recurrent ischemia. Six 
patients died, two of myocardial re-infarction, one of cancer, one of an infectious disease with 
multiorgan failure, and two died without known reason. Fifteen patients experienced a non-
fatal re-infarction. Table 3 summarises all first events in relation to the glucometabolic status 
classified in-hospital. 
 
The Kaplan-Meier curves for patients with normal (n=119) or abnormal glucose regulation 
(n=105) classified by an OGTT in-hospital are shown in Figure 1. The probability of 
remaining free from a new clinical event did not differ between the two groups (Log-Rank, 
p=0.4).  In a multivariate analysis adjusting for potential confounders the association 
remained non-significant between the groups (adjusted HR 0.81 (95 % CI 0.48-1.38), 
p=0.44).  
 
Long-term prognosis was also compared between groups of patients classified into normal 
(n=151) and abnormal glucose regulation (n=50) based on an OGTT performed in a stable 
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condition at three-month follow-up. No significant difference in survival free of composite 
end-point was found between the groups (Figure 2, Log-Rank, p=0.3). Adjusting for potential 
confounders did not change the results significantly (adjusted HR 0.68 (95 % CI 0.34-1.36), 
p= 0.27). Nine patients experienced a new clinical event before the OGTT classification was 
performed at three months. Among these nine patients, seven and two patients were classified 
into the abnormal and normal glucose regulation group, respectively, based on the in-hospital 
OGTT. 
  
Discussion
Our main result was that stable STEMI patients without previously known diabetes have an 
excellent long-term prognosis independent of newly detected abnormal glucose regulation 
made by an OGTT screening either in-hospital or at three-month follow-up. 
Large prospective studies have demonstrated both admission and fasting blood glucose levels 
to be independent predictors of long-term mortality in non-diabetic acute MI patients whether 
treated by primary PCI or not [19-24]. However, data evaluating the prognostic importance of 
an OGTT performed during or early after an acute MI in patients without previously known 
diabetes are scarce. The timing of testing patients for abnormal glucose regulation after an 
acute MI is also uncertain. Recommendation of early screening of acute MI patients with an 
OGTT in order to detect high-risk patients in the recent European guidelines is mainly based 
on the follow-up study of the GAMI trial [8,9]. In this follow-up study, abnormal glucose 
regulation classified by an OGTT day four or five post-MI was associated with worse clinical 
outcome during a median follow-up time of about three years [8].    
Our study is the second study (after the GAMI study) to evaluate early OGTT during an acute 
STEMI as a prognostic tool, in patients without previously known diabetes, and the first study 
who compared the prognostic value of an OGTT based classification in-hospital and after 
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three months. The low event rate in the present study prevents firm conclusions about the 
prognostic value of OGTT screening in patients with acute STEMI. There was a non-
significant trend towards increased hazard in patients with abnormal vs. normal glucose 
regulation and a real difference between groups may have been detected if the sample size 
was larger. However, our results are not in line with the similar sized GAMI study and may 
challenge the present guidelines, which emphasize the importance of early testing of all 
patients with acute MI, especially in the modern era of acute revascularization of STEMI 
patients. 
The excellent prognosis found in our study, regardless of the glucometabolic status, may 
partly be explained by the low proportion of patients classified with type 2 diabetes in-
hospital and at three months (11 % and 5 %, respectively). Nevertheless, patients classified 
with abnormal compared to normal glucose regulation in-hospital and at three-month follow-
up had significantly higher fasting values of HbA1c, circulating levels of insulin and 
proinsulin, and higher HOMA-IR score when measured both acutely and in a stable condition. 
These results correspond to another trial with acute MI patients showing that HbA1c and 
proinsulin were in the lowest range in patients with normal glucose regulation, intermediate in 
patients with impaired glucose tolerance, and highest in patients with type 2 diabetes [25]. 
The present results suggest that the abnormal glucose regulation found in these STEMI 
patients not only seem to be a transient stress-induced response, but also may be a result of 
underlying insulin resistance. 
 
The overall mortality rate in the present study was 2.7 %. None died in-hospital and only one 
patient died during the first 30 days. Nine patients (7 with abnormal glucose regulation) 
experienced a new clinical event before the OGTT classification was performed at three-
month follow-up. However, a low overall incidence of clinical events was found during the 
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first three months of follow-up, suggesting that a early OGTT based classification of the 
glucometabolic status in order to identify high risk patients with worse prognosis is possibly 
of limited importance in low risk patients with a primary PCI treated STEMI.  
The low overall incidence of clinical events reported in our study may partly be explained by 
the inclusion criteria. Unstable patients with cardiogenic shock, renal failure, ongoing chest 
pain, nausea and persistent hyperglycaemia were excluded from the study, probably making a 
selection bias towards more glucometabolically normal patients with better prognosis. 
Furthermore, the patients included were relatively young and previous studies have shown a 
close relationship between newly diagnosed abnormal glucose regulation and age [8,26-28]. 
Additionally, a high proportion of our patients were diagnosed with single-vessel disease 
during coronary angiography [10], which may have contributed to the low event-rate observed 
in both groups. 
 
Systematic use of recommended treatment (evidenced based medications and 
revascularisation) has been shown to have a favourable impact on one-year prognosis in 
patients with diabetes and coronary artery disease [29]. Patients in the present study were all 
treated by primary PCI in addition to a high proportion of patients on evidence based 
secondary prevention. All patients were treated according to guidelines regardless of 
glucometabolic status and this may explain the excellent prognosis observed in this STEMI 
population. Transient hyperglycaemia in patients with acute MI without known diabetes is 
common and is associated with worse outcome [19,24]. However, it has been difficult to 
prove that glucose control by insulin-glucose infusion [30] or insulin-glucose-potassium 
infusion [31], improve survival in patients with acute MI. 
The European guidelines on diabetes, pre-diabetes, and cardiovascular diseases recommend 
that patients with cardiovascular disease without known diabetes should be investigated with 
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an OGTT [9], but whether the OGTT should be performed early after a first cardiovascular 
event or later in a stable condition is not defined. The present results suggest that OGTT 
screening of patients with acute STEMI without known diabetes should be performed in a 
stable condition during the post-MI follow-up. 
Study limitations 
The present study has certain limitations such as a possible selection bias towards more 
glucometabolically normal patients due to the exclusion of patients who were 
hemodynamically unstable, severe renal failure and persistent hyperglycaemia. Accordingly, 
patients included, were somewhat younger than expected from a general STEMI population, 
had relatively few comorbidities and mainly one-vessel disease. It is possible that different 
results would be obtained in older MI patients since high age has been shown to be associated 
with ischemia related hyperglycaemia and poor glycemic control [28].  
All aspects taken together may explain the overall low incidence of clinical events during the 
follow-up period, but may also reflect the advances in modern treatment of STEMI with 
primary PCI in all patients and optimal post-infarction treatment. The association between 
abnormal glucose regulation classified by an OGTT and clinical outcome should be further 
investigated in forthcoming studies including primary PCI treated STEMI patients, with a 
prolonged follow-up period, using major cardiovascular events as a primary end-point. 
 
Conclusion
 
Patients with a primary PCI treated STEMI, without previously known diabetes, appear to 
have an excellent long-term prognosis independent of the glucometabolic state classified by 
an OGTT in-hospital or at three-month follow-up. 
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Figure legends: 
 
 
Figure 1 Kaplan-Meier curves, survival free of composite end-point for patients with normal 
(NGR) and abnormal glucose regulation (AGR) classified by an OGTT in-hospital (A) 
and after three months (B). 
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Table 1 Clinical characteristic of patients with STEMI according to glucometabolic 
classifications by an OGTT in-hospital and after three months.  
 In-hospital  At three-month follow-up  
 NGR 
(n=119) 
AGR 
(n=105) 
 
P 
NGR 
(n=151) 
AGR 
(n=50) 
 
P 
Age (years) 55 (50,63) 60 (54,71) <0.001 57 (51, 65) 61 (52, 72) 0.04 
Men    106 (89.1) 79 (75.2) <0.01 129 (85.4) 36 (72.0) 0.03 
Previous disorders       
Treated dyslipidaemia 11 (9.2) 9 (8.6) 0.86 15 (9.9) 4 (8.0) 0.47 
Treated hypertension 25 (21) 33 (31.4) 0.32 38 (25.2) 17 (34.0) 0.23 
Previous acute MI   9 (7.6) 7 (6.7) 0.08 10 (6.6) 4  (8.0) 0.48 
Previous angina pectoris             5 (4.2) 2 (1.9) 0.33 6 (4.0) 1 (2.0) 0.45 
Current smoker 65 (54.6) 44 (41.9) 0.06 67 (44.4) 24 (48.0) 0.66 
Body mass index (kg/m2)       25.9 (24.5, 28.7) 26.1 (24.3, 28.6) 0.82 26.1 (24.4, 28.5) 25.7 (24.1, 28.7) 0.73 
Waist circumference  100 (94, 107) 99 (94, 107) 0.86 101 (94, 107) 98 (94, 107) 0.92 
Cholesterol (mmo/L) 5.2 (4.5, 5.8) 5.1 (4.4, 5.8) 0.52 4.1 (3.8, 4.6) 4.0 (3.6, 4.8) 0.43 
LDL-cholesterol  (mmol/ L) 3.4 (2.7, 4.2) 3.3 (2.7, 4.0) 0.54 2.2 (1.8, 2.6) 2.1 (1.7, 2.6) 0.42 
Triglycerides (mmo/ L)   1.4 (1.0,1.8) 1.2 (0.9,1.8) 0.11 1.2 (0.9, 1.6) 1.2 (1.1, 1.6) 0.64 
       
Stents  114 (95.8) 101 (96.2) 0.88 143 (94.7) 49 (98.0) 0.30 
One-vessel disease 78 (65.5) 61 (58.1) 0.25 92 (60.9) 30 (60.0) 0.91 
Left main disease 47 (39.5) 42 (40.0) 0.94 58 (38.4) 21 (42.0) 0.65 
IIb / IIIa inhibitors 37 (31.1) 42 (40.0) 0.17 54 (35.8) 19 (38.0) 0.78 
TnT peak value (ug/ L)  4.47 (2.39, 7.32) 5.63 (2.78,10.89) 0.03 4.85 (2.45, 8.31) 4.97 (2.38, 
10.25) 
0.47 
       
Measured at three-month.       
LVEF1 (%) 64 (57, 70) 62 (52,69) 0.13 63.5 (56, 70) 63.5 (51, 69) 0.47 
Infarct size2 (%) 9 (0, 25) 20 (4.5, 32) <0.001 13 (0, 27) 21.5 (0, 43) 0.04 
       
Medication at discharge from CCU  
and after three months. 
      
Aspirin 119 (100) 105 (100)  150 (99.3) 50 (100) 0.57 
Clopidogrel 118 (99.2) 104 (99.0) 0.93 143 (94.7) 46 (92.0) 0.49 
-blockers 96 (80.7) 85 (81.0) 0.96 142 (94.0) 46 (92.0) 0.61 
Lipid lowering agents  118 (99.2) 103 (99.1) 0.49 146 (96.7) 48 (96.0) 0.82 
ACEIs 19 (16) 17 (16.2) 0.96 52 (34.4) 17 (34.0) 0.96 
ARBs 8 (6.7) 10 (9.5) 0.44 21 (13.9) 4 (8.0) 0.27 
 
Data are presented as median values (25, 75 percentiles) or proportions. 
         ACEIs: angiotensin-converting enzyme inhibitors, AGR: abnormal glucose regulation, acute 
MI: acute myocardial infarction, ARBs: angiotensin receptor blockers, CCU: coronary care 
unit, NGR: normal glucose regulation, TnT peak level: serum peak level of cardiac specific 
Troponin T. 1,2Measured at three months by SPECT analysis, 1LVEF: left ventricular ejection 
fraction, 2infarct size in % of left ventricular mass. 
 
 
 
 
 
 
 
 
 
 
 20
Table 2 Biochemical variables in patients according to glucometabolic status classified by an 
OGTT in-hospital and at three-month.  
Data are presented as median values (25, 75 percentiles) 
 
 
NGR 
(in-hospital) 
(n=119) 
AGR 
(in-hospital) 
(n=105) 
 
 
P 
NGR 
(at three-month) 
(n=151) 
AGR 
(at three-month) 
(n=50) 
 
 
P 
HbA1c (%) 5.5 (5.3, 5.7) 5.6 (5.4, 5.8) <0.01 5.5 (5.4, 5.7) 5.8 (5.5, 6.2) <0.0001 
Insulin (pmol/ L) 66 (46, 87)  73 (53,108) 0.03 63 (39, 82) 75 (47, 112) 0.02 
C-peptid (pmol/ L)  788 (638, 1026) 1026 (728, 1241) <0.001 834 (636, 1077) 893 (728, 1129) 0.11 
Proinsulin (pmol/ L) 6.8 (4.7, 10.4) 8.6 (5.8, 13.9) 0.02 5.4 (4.3, 8.5) 7.5 (5.4, 10.3) 0.01 
HOMA-IR (mU mmol-1 L-1) 2.45 (1.63, 3.36) 3.00 (2.11, 4.92) <0.001 2.20 (1.45, 3.23) 3.15 (2.08, 4.99) <0.01 
Proinsulin: insulin ratio 0.12 (0.08, 0.19) 0.13 (0.08, 0.18) 0.87 0.10 (0.07, 0.15) 0.12 (0.07, 0.18) 0.41 
AGR: abnormal glucose regulation, NGR: normal glucose regulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Number of first clinical events according to glucometabolic status classified by an 
OGTT in-hospital in patients (n=224) with STEMI. 
 
 
Type of event 
NGR 
(n=119) 
 
IFG 
(n=12) 
IGT 
(n=69) 
DM 
(n=24) 
 
 
Total 
Death 1 1 4 0 6 
Non-fatal re-infarction 9 0 5 1 15 
Recurrent ischemia 20 0 8 5 33 
Stroke 4 0 0 0 4 
SUM 34 1 17 6 58 
NGR: normal glucose regulation, IFG: impaired fasting glucose, IGT: impaired glucose 
tolerance, DM: type 2 diabetes mellitus. 
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Increased levels of CRP and MCP-1 are associated
with previously unknown abnormal glucose
regulation in patients with acute STEMI:
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Abstract
Background: Inflammation plays an important role in the pathophysiology of both atherosclerosis and type 2
diabetes and some inflammatory markers may also predict the risk of developing type 2 diabetes. The aims of the
present study were to assess a potential association between circulating levels of inflammatory markers and
hyperglycaemia measured during an acute ST-elevation myocardial infarction (STEMI) in patients without known
diabetes, and to determine whether circulating levels of inflammatory markers measured early after an acute STEMI,
were associated with the presence of abnormal glucose regulation classified by an oral glucose tolerance test
(OGTT) at three-month follow-up in the same cohort.
Methods: Inflammatory markers were measured in fasting blood samples from 201 stable patients at a median time
of 16.5 hours after a primary percutanous coronary intervention (PCI). Three months later the patients performed a
standardised OGTT. The term abnormal glucose regulation was defined as the sum of the three pathological glucose
categories classified according to the WHO criteria (patients with abnormal glucose regulation, n = 50).
Results: No association was found between inflammatory markers and hyperglycaemia measured during the acute
STEMI. However, the levels of C-reactive protein (CRP) and monocyte chemoattractant protein-1 (MCP-1) measured
in-hospital were higher in patients classified three months later as having abnormal compared to normal glucose
regulation (p = 0.031 and p = 0.016, respectively). High levels of CRP (≥ 75 percentiles (33.13 mg/L)) and MCP-1
(≥ 25 percentiles (190 ug/mL)) were associated with abnormal glucose regulation with an adjusted OR of 3.2
(95% CI 1.5, 6.8) and 7.6 (95% CI 1.7, 34.2), respectively.
Conclusion: Elevated levels of CRP and MCP-1 measured in patients early after an acute STEMI were associated
with abnormal glucose regulation classified by an OGTT at three-month follow-up. No significant associations were
observed between inflammatory markers and hyperglycaemia measured during the acute STEMI.
Background
Increased prevalence of unknown impaired glucose tol-
erance and type 2 diabetes has been shown in patients
suffering an acute myocardial infarction (AMI) [1]. Both
the short- and long-term prognoses after an AMI are
worse among individuals with abnormal compared to
individuals with normal glucose regulation [2]. Accord-
ing to guidelines, it is important to diagnose these high-
risk patients with abnormal glucose regulation in order
to initiate lifestyle intervention and optimal medical
treatment [3].
We have recently shown that high levels of HbA1c,
admission glucose, and fasting plasma glucose measured
early in-hospital in patients with an acute ST-elevation
myocardial infarction (STEMI) were predictive to identify
patients with abnormal glucose regulation at three-month
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follow-up [4]. We also demonstrated poor reproducibility
of an oral glucose tolerance test (OGTT) performed early
after an acute STEMI compared to a new test in a stable
condition three months later [4].
There is considerable evidence that inflammation
plays an important role in the pathophysiology of both
atherosclerosis [5] and type 2 diabetes [6] and some
inflammatory markers may also predict the risk of
developing type 2 diabetes [7]. Additionally, inflamma-
tion has been suggested to be the bridging link between
abnormalities in glucose metabolism and atherosclerotic
disorders [8] In order to elucidate a possible association
between hyperglycaemia, abnormal glucose regulation
and inflammation in STEMI patients without known
diabetes we chose to investigate a broad panel of pro-
and anti-inflammatory markers. The acute phase reac-
tant C-reactive protein (CRP), the pro-inflammatory
markers (interleukin 6 (IL-6), interleukin 8 (IL-8),
monocyte chemoattractant protein-1 (MCP-1), tumor
necrosis factor a (TNF-a)), soluble CD40 ligand
(sCD40L), the anti-inflammatory marker adiponectin,
the matrix metalloproteinase-9 (MMP-9) and its inhibi-
tor (tissue inhibitor of metalloproteinase 1 (TIMP-1))
were investigated. We hypothesized that STEMI patients
having abnormal glucose regulation would present with
an increased pro-inflammatory profile.
The aims of the study were 1) to assess a potential
association between circulating levels of inflammatory
markers and hyperglycaemia measured during an acute
STEMI in patients without known diabetes and 2) to
identify a possible association between circulating levels
of inflammatory markers measured acutely and abnor-
mal glucose regulation classified by an OGTT at three-
month follow-up in the same cohort.
Methods
Study population
The patient population has been described in detail else-
where [4]. In brief, patients with a primary percutanous
coronary intervention (PCI) treated STEMI were
included if they were stable, without chest pain or nau-
sea, age < 85 years and with serum creatinine < 200
umol/L. Patients with previously known type 2 diabetes
or persistent hyperglycaemia were excluded. Patients
with persistent hyperglycaemia were defined as patients
with both admission plasma glucose > 11 mmol/L and a
fasting capillary glucose level > 8 mmol/L before an
OGTT was performed. STEMI was defined as ST-seg-
ment elevation of ≥ 2 mm in two or more contiguous
chest leads, ≥ 1 mm in two or more limb leads, or new
left bundle-branch block, together with typical symp-
toms (chest pain or discomfort > 20 min duration).
The Regional ethics committee approved the study
and all patients provided written and oral informed
consent.
Laboratory methods
Admission plasma glucose concentration was analysed
from blood samples taken in the catheterisation
laboratory as soon as possible after PCI. Further blood
samples were drawn after an overnight fast for deter-
mination of glucose, HbA1c, for routine analyses by
use of conventional methods and for determination of
CRP, MCP-1, TNF-a, IL-6, sCD40L, IL-8, MMP-9,
TIMP-1, IL-18, and adiponectin. Serum was prepared
by centrifugation within 1 hour at 2500 g for 10 min
and used for all analyses, except MCP-1, which was
determined in citrated plasma (0.129 mmol/L in dilu-
tion 1:10) and sCD40L determined in EDTA plasma,
stored on ice and separated within 30 min by centrifu-
gation at 4°C and 3000 g for 20 min to obtain platelet-
poor plasma. All blood samples were stored at -80°C
until analysis.
CRP and IL-18 were determined by enzyme-linked
immunosorbent assays (DRG Instruments, Marburg/
Lahn, Germany, and Medical Biological Laboratories,
Naku-ku, Nagoya, Japan, respectively). MCP-1, MMP-9,
TIMP-1, IL-6, IL-8, TNF-a, adiponectin and sCD40L
were all measured by enzyme immunoassays from R&D
Systems Europe (Abingdon, Oxon, UK).
In our laboratory, the inter-assay coefficient of varia-
tion were as follows, CRP < 5%, MCP-1 9.0%, IL-6
10.5%, IL-8 10.5%, IL-18 6.5%, TNF-a 8.5%, adiponectin
9.5%, MMP-9 7.4%, TIMP-1 4.4%, and sCD40L 9.5%.
Serum cardiac specific Troponin T (TnT) was mea-
sured by electrochemiluminescence technology for
quantitative measurement (Elecsys 2010, Roche, Man-
nheim, Germany). The inter-assay coefficient of varia-
tion was 7%. TnT maximum was defined as the
maximum value measured in each patient during the
acute STEMI.
Follow- up
Three months after the initial hospitalisation clinical
examination and a standardised oral glucose tolerance
test (OGTT) (75 g glucose in 200 ml water with plasma
glucose measurements at 0 and 120 min) were per-
formed [9]. The classification of glucometabolic state
was based on the result of the OGTT and the patients
were divided into one of the following four categories
defined according to the World Health Organisation cri-
teria [10] (glucose levels given in mmol/L):
Normal Glucose Tolerance (NGT) = OGTT (0 min) <
6.1 and OGTT (2 h) < 7.8
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Impaired Fasting Glucose (IFG) = OGTT (0 min) ≥
6.1 < 7.0 and OGTT (2 h) < 7.8
Impaired Glucose Tolerance (IGT) = OGTT (0 min) <
7.0 and OGTT (2 h) ≥ 7.8 < 11.1
Type 2 diabetes (T2DM) = OGTT (0 min) ≥ 7.0 and/
or OGTT (2 h) ≥ 11.1.
The term abnormal glucose regulation was defined as
the sum of IFG, IGT and T2DM.
Left ventricular ejection fraction and infarct size
expressed as percent of left ventricular mass were
assessed at rest at three-month follow-up by Single
Photon Emission Computed Tomography imaging with
technetium 99 m-tetrofosmin [11].
Statistics
The study design was a cohort study and the outcome
was defined as abnormal glucose regulation. We
hypothesised an association between inflammatory vari-
ables and the state of glucose regulation. Continuous
variables were categorised into quartiles. A linear trend
analysis across the quartiles of an inflammatory marker
identified the cut off point used. The Mantel-Haenszel
method was used to highlight potential effect modifica-
tion by the Breslow-Day test of heterogeneity and to
quantify potential confounders [12]. Additional informa-
tion is available online [Additional file 1: Supplemental
Table S1]. The following risk factors were analysed as
potential confounders; gender, age, current smoking,
treated hypertension, TnT maximum, body mass index,
cholesterol, triglycerides, CRP and MCP-1. A logistic
regression model, including a backward elimination pro-
cedure was performed to adjust for the confounders.
Continuous variables are presented as median and 25,
75 percentiles and categorical variables as proportions.
The correlations between the investigated variables were
assessed by use of Spearman’s rho and adjustments were
performed using a multivariate analysis with logarithmi-
cally transformed data. The STROBE guidelines were
followed [13]. A value of p < 0.05 was considered statis-
tically significant. All analyses were performed using
Epi-info software, 2005, version 3.3.2, except Spearman
correlation coefficient analyses and multiple regressions,
which were made by use of SPSS software, 2006, version
15.0 (SPSS, Chicago, L).
Results
Baseline characteristics
Two hundred and one patients with a primary PCI trea-
ted STEMI were enrolled in the study [4]. Baseline char-
acteristics are shown in Table 1. Notably, BMI was
26 kg/m2, 82% were men and 61% had single vessel
disease. Fasting blood samples were drawn at a median
time of 20 h and 20 min after the occurrence of symp-
toms and 16 h and 35 min after the primary PCI.
The plasma glucose concentration at admission was
6.9 (6.0, 7.8) mmol/L, the fasting plasma glucose
5.3 mmol/L (4.9, 5.9) and HbA1c 5.5% (5.3, 5.8). As pre-
viously reported, patients defined with abnormal glucose
regulation were older, there were more women, and
they had significantly higher levels of HbA1c, admission
plasma glucose, and fasting plasma glucose measured
in-hospital, compared to patients with normal glucose
regulation [4].
Follow-up characteristics
All patients were reached to follow up. However, one
patient did not perform the OGTT because the level of
fasting glucose measured was above 7 mmol/L. At
three-month follow-up the levels of fasting plasma glu-
cose and HbA1c were 5.2 mmol/L (4.8, 5.6) and 5.6%
(5.4, 5.8), respectively. The prevalence of abnormal glu-
cose regulation based on the OGTT classification was
Table 1 Baseline characteristics of the total population
(n = 201)
Patients
Age (years) 58 (51, 67)
Male 185 (82.6%)
Previous disorder:
Myocardial infarction 16 (7.1%)
Angina pectoris 7 (3.1%)
Hypertension (treated) 58 (25.9%)
Hyperlipidaemia (treated) 20 (8.9%)
Status at baseline
Current smoker 109 (48.7%)
TnT maximum (ug/L) 4.70 (2.45, 8.92)
BMI (kg/m2) 26 (24.4, 28.7)
Waist circumference (cm) 100 (94, 107)
Stent in culprit lesion 215 (96.0%)
Gp IIb/IIIa antagonist treated 79 (35.3%)
Single -coronary vessel disease 139 (62.1%)
Double-coronary vessel disease 64 (28.6%)
Triple-coronary vessel disease 21 (9.4%)
Time from symptoms to balloon (min) 219 (140, 378)
Medication at three months (n = 201)
Aspirin 200 (99.5%)
Clopidogrel 189 (94%)
b-blockers 188 (93.5%)
Lipid lowering agents 194 (96.5%)
Angiotensin converting enzyme-inhibitors 69 (34.3%)
Angiotensin II-receptor blockers 25 (12.4%)
Glucose lowering medication 0
LVEFa (%) 64 (56, 70)
Infarct sizea, % of left ventricular mass 14.0 (0.0, 29.0)
Data are presented as median (25, 75 percentiles) values or proportions.
BMI: body mass index, LVEF: left ventricular ejection fraction, TnT maximum:
serum cardiac specific Troponin T maximum.aLVEF and infarct size were
measured at three-month follow-up by SPECT.
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25% (n = 50). The prevalence of impaired fasting glu-
cose, impaired glucose tolerance, and type 2 diabetes
were 5.5% (n = 11), 14.4% (n = 29) and 5% (n = 10),
respectively. The medications for secondary prevention
recorded were according to current guidelines, i.e. 99.5%
were on aspirin and 96.5% were on lipid lowering agents
(Table 1).
Inflammatory markers and hyperglycaemia
As can be seen from Table 2, there were no associations
between admission glucose and the inflammatory mar-
kers measured whereas significant correlations were
observed between fasting glucose and IL-6 (p = 0.004)
and adiponectin (p = 0.038). However, after adjustment
for age and TnT maximum measured in-hospital, no
significant associations were found (p = 0.14 and
p = 0.095, respectively).
Inflammatory markers and abnormal glucose regulation
Elevated levels of CRP (p = 0.031) and MCP-1 (p =
0.016) measured in-hospital were found in patients clas-
sified with abnormal glucose regulation at three-month
follow-up (Table 3). There was no difference between
the two groups according to the other inflammatory
markers measured (Table 3). Furthermore, only a weak
correlation between MCP-1 and CRP was found (r =
-0.14, p = 0.049).
When dividing the MCP-1 and CRP levels into quar-
tiles, there were significant trends for the presence of
abnormal glucose regulation with increased levels of
both biomarkers (p = 0.005 and p = 0.016, respectively),
identifying a threshold for MCP-1 at the 25 percentile
(190 ug/mL) and for CRP at the 75 percentile (33.13
mg/L) (Figure 1A and 1B). In univariate analyses, high
levels of CRP (≥ 75 percentile) and MCP-1 (≥ 25
percentile) in-hospital were associated with abnormal
glucose regulation classified at three-month (p = 0.007
and p = 0.004, respectively) (Table 4). CRP remained
associated with abnormal glucose regulation after adjust-
ment for potential confounders with an OR 3.24 (95%
CI 1.54, 6.83) (Table 4). Triglycerides were shown to
modify the association between MCP-1 and abnormal
glucose regulation (Table A online). Consequently, the
patients were divided into two strata with high and low
triglyceride levels. High levels of MCP-1 were indepen-
dently associated with abnormal glucose regulation in
150 patients with triglycerides below the 75th percentile
(1.8 mmol/L) with an OR 7.56 (95% CI 1.67, 34.18).
Discussion
The main results of the present study were that elevated
levels of CRP and MCP-1 measured in patients early
after an acute STEMI were associated with abnormal
glucose regulation defined at three-month follow-up.
Additionally, during the acute STEMI, there were weak,
non-significant associations between fasting glucose and
IL-6 and adiponectin, while there was no association
between admission glucose and the inflammatory mar-
kers measured.
Inflammatory markers and hyperglycaemia
During experimental conditions, induction of hypergly-
caemia in humans has been shown to increase circulat-
ing levels of cytokines and the effect was more
pronounced in subjects with impaired glucose tolerance
suggesting a causal role of hyperglycaemia in the activa-
tion of the inflammation in diabetes [14]. Furthermore,
hyperglycaemia at admission has been reported to be
associated with increased risk of in-hospital mortality
Table 2 Correlations between the inflammatory markers
and admission plasma glucose (APG) and fasting plasma
glucose (FPG), all measured acutely in-hospital
Variables APG FPG
rs p rs p
CRP mg/L 0.04 NS 0.13 NS
MCP-1 pg/mL 0.05 NS -0.11 NS
TNF-a pg/mL 0.06 NS -0.02 NS
IL-6 pg/mL -0.04 NS 0.20 0.004
sCD40L pg/mL -0.06 NS -0.05 NS
IL-8 pg/mL -0.12 NS -0.12 NS
TIMP-1 ng/mL 0.06 NS 0.03 NS
MMP-9 ng/mL 0.13 NS 0.13 NS
IL-18 pg/mL -0.03 NS -0.04 NS
Adiponectin ng/mL -0.03 NS 0.15 0.04
rs indicate Spearman correlation coefficient.
Abbreviations: see main text.
NS: non-significant.
Table 3 Levels of inflammatory markers measured
in-hospital related to normal (NGR) and abnormal
glucose regulation (AGR) categorised by an OGTT after
three months
Variables NGR
(n = 151)
AGR
(n = 50)
P
CRP mg/L 10.99 (5.95, 30.0) 20.91(8.40, 41.98) 0.031
MCP-1 pg/mL 218 (185, 268) 241 (205, 301) 0.016
TNF-a pg/mL 1.51 (1.25, 2.06) 1.58 (1.26, 2.06) 0.996
IL-6 pg/mL 17.16 (11.22, 28.04) 20.88 (13.76, 31.00) 0.131
CD40L pg/mL 63.3 (44.5, 97.4) 64.6 (43.3, 88.8) 0.599
IL-8 pg/mL 15.1 (13.6, 17.8) 15.4 (13.2, 19.4) 0.432
TIMP-1 ng/mL 190 (162, 217) 199 (163, 220) 0.911
MMP-9 ng/mL 502 (341, 664) 539 (414, 748) 0.254
IL-18 pg/mL 269 (203, 333) 288 (239, 359) 0.096
Adiponectin ng/mL 4794 (3006, 7759) 4385 (2806, 7075) 0.474
Median values (25, 75 percentiles) are given.
Abbreviations: see main text.
P-values refer to difference between groups.
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and poor long-term outcome [15-17]. There are, how-
ever, no guidelines defining the level of pathological
hyperglycaemia at admission with an acute myocardial
infarction [17].
It has been shown that patients with a primary PCI
treated STEMI generate a marked, short-term increase
in circulating levels of inflammatory markers [18] and
higher levels of CRP and IL-6 in patients with acute
myocardial infarction and diabetes compared to patients
without diabetes have also been reported [19]. In the
present study we could, however, not reveal any associa-
tion between the acute hyperglycaemia and the inflam-
matory responses. The relatively few patients with
hyperglycaemia at admission may partly explain these
negative results. In addition, we may have missed the
peak levels of the measured inflammatory markers by
the delayed sampling time point. The association found
between fasting glucose and IL-6 and adiponectin prob-
ably reflect a relation to infarct size because it was no
longer significant after adjustment for TnT maximum.
Associations between inflammatory markers and
abnormal glucose regulation
We have recently shown that in patients with a primary
PCI treated STEMI, a very early OGTT should probably
not be recommended because of lack of reproducibility
[4]. However, high levels of admission glucose, fasting
glucose, and HbA1c in these patients were shown to be
associated with abnormal glucose regulation defined at
three-month follow-up [4]. In the present study, search-
ing for novel biomarkers that may associate with abnor-
mal glucose regulation, we found that high levels of CRP
and MCP-1 measured early after an acute STEMI were
associated with abnormal glucose regulation diagnosed in
a stable cituation. The associations found between high
levels of CRP and MCP-1 measured acutely and abnor-
mal glucose regulation defined three months later might
be influenced by the acute STEMI, which are known to
release several inflammatory mediators from the necrotic
myocardium into the circulation [20].
Our findings may be interpreted along with previous
results showing higher levels of CRP in patients with
abnormal compared to those with normal glucose regu-
lation [21] thus the high levels of CRP measured acutely
may reflect a low-grade systemic inflammation in glu-
cose intolerant patients.
MCP-1 levels have been reported to be elevated in
patients with an acute myocardial infarction [22] and
poor glycemic control has been suggested to induce
high levels of MCP-1 in diabetic patients [23]. Further-
more, increased monocyte recruitment into the suben-
dothelial space has been shown in patients with diabetic
angiopathy and MCP-1 seems to play a key role in this
process [24]. In our study, the association between high
levels of MCP-1 and abnormal glucose regulation may
indicate that patients with an abnormal glucometabolic
status do present with high levels of MCP-1 before the
acute STEMI or it might be suggested that patients with
abnormal glucose regulation respond with higher levels
of MCP-1 in the acute phase, compared to those with
normal glucose regulation.
MCP-1 levels have been shown to correlate with tri-
glyceride levels in post-menopausal women [25] and in
patients with diabetes [23]. In our study the association
between MCP-1 and abnormal glucose regulation was
present in the majority of the patients, but not in
patients with triglycerides above 1.8 mmol/L, suggesting
that in these patients the high levels of triglycerides may
mask the association between MCP-1 and glucose
regulation.
Figure 1 Odds ratios of having abnormal glucose regulation
classified three months after an acute STEMI by quartiles of
MCP-1 (pg/mL, panel A) and CRP (mg/L, panel B) measured in-
hospital. P for trend, (A, p = 0.005) and (B, p = 0.016).
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CRP and MCP-1 were associated with abnormal glu-
cose regulation independently of each other, indicating
that these markers probably are involved in different
pathological processes associated with type 2-diabetes.
MCP-1 and IL-8 are functionally related, potent che-
moattractants both being shown to be involved in the
atherosclerotic process [26]. It has previously been
reported that fasting levels of IL-8 correlated with BMI
both in subjects with normal and impaired glucose tol-
erance [27]. In obese subjects without coronary heart
disease, the post-load levels of IL-8 increased after an
OGTT in subjects with impaired glucose tolerance com-
pared to normoglycaemic weight-matched individuals
[27] However, we did not found any association between
IL-8 and abnormal glucose regulation.
Elevated levels of IL-18 have been associated with an
increased risk of developing type 2-diabetes [28]. Also
high levels of MMP-9 and TIMP-2 have been found in
patients with an acute coronary syndrome and type 2
diabetes, probably reflecting an abnormal extracellular
matrix metabolism in these patients [29]. On the con-
trary, circulating levels of adiponectin, which is an anti-
atherogenic, anti-inflammatory and insulin-sensitizing
adipokine, have been shown to be lower in patients with
type 2 diabetes and macro vascular disease than those
without [30]. We found, however, no associations
between abnormal glucose regulation and the levels of
IL-18, MMP-9, TIMP-1, and adiponectin. This may be
explained by the fact that only a small number of our
patients were classified as having type 2-diabetes.
Almost all the patients in the present study were trea-
ted according to guidelines for secondary prevention
with medication, which included lipid lowering agents
and anti-platelet treatment. However, glucose lowering
medication, which could have had a confounding effect
on the glucometabolic classification, was not introduced.
Study limitations
Unstable patients with cardiogenic shock, renal failure,
ongoing chest pain, nausea and persistent hyperglycaemia
were excluded from the study, possibly making a selec-
tion bias towards more glucometabolically normal
patients.
Conclusion
Elevated levels of CRP and MCP-1 measured early after
a primary PCI treated STEMI in patients without pre-
viously known diabetes were associated with abnormal
glucose regulation classified by an OGTT at three-
month follow-up indicating an important role of low
grade inflammation in glucose regulation. There was
however, non-significant association between inflamma-
tory markers and hyperglycaemia during the acute
STEMI in the same cohort
Additional material
Additional file 1: Stratified analysis on major potential confounders
using the Mantel-Haenszel method. Table S1 shows identified effect
modifiers and potential confounders in the associations between CRP
and AGR, and MCP-1 and AGR by use of the Mantel-Haenszel method.
Abbreviations: see main text.
Acknowledgements
We thank Vibeke Bratseth for laboratory assistance and Anne-Kari Brun who
coordinated the outpatient controls.
This work was supported by the Stein Erik Hagen Foundation for Clinical
Heart Research, the South-Eastern Norway Regional Health Authority and
The Norwegian Diabetes Association, Oslo, Norway.
Author details
1Center for Clinical Heart Research, Oslo University Hospital, Ullevål, Oslo,
Norway. 2Department of Cardiology, Oslo University Hospital, Ullevål, Oslo,
Norway. 3Center of Clinical Research, Unit of Epidemiology and Biostatistics,
Oslo University Hospital, Ullevål, Oslo, Norway. 4Center for Heart Failure
Research, Oslo University Hospital, Ullevål, Oslo, Norway. 5Faculty of
Medicine, University of Oslo, Oslo, Norway. 6Nuclear Medicine, Oslo
University Hospital, Ullevål, Oslo, Norway.
Authors’ contributions
ECK performed the statistical analysis of the data presented and drafted the
manuscript.
MA made substantial contribution with statistical analysis. GØA contributed
with the conception and design of the study. ECK, IS, MA, JE, AM, HA and
GØA participated in the study design and interpretation and revised the
Table 4 Crude and adjusted OR of the association between high levels of CRP and MCP-1 measured in-hospital and
abnormal glucose regulation defined by an OGTT three months later using logistic regression analyses
AGR AGR AGR
TG < 1.8 mmol/l
(n = 150)
AGR
TG ≥ 1.8 mmol/l
(n = 49)
OR (crude)
(95% CI)
P OR (adjusted)
(95% CI)
P OR (adjusted)
(95% CI)
P OR (adjusted)
(95% CI)
P
CRPa
(≥ 33.13 mg/L)
2.58
(1.29, 5.14)
0.007 3.24
(1.54, 6.83)
0.002
MCP-1b
(≥ 190 pg/mL)
4.82
(1.64, 14.20)
0.004 7.56
(1.67, 34.18)
0.009 1.81
(0.16,19.87)
0.626
TG: triglycerides. AGR: abnormal glucose regulation. Abbreviations: see main text.
a Adjusted for identified confounders (gender and MCP-1).
b Stratified for triglycerides as an effect modifier and adjusted for identified confounders (age, gender, treated hypertension, TnT maximum and CRP).
Knudsen et al. Cardiovascular Diabetology 2010, 9:47
http://www.cardiab.com/content/9/1/47
Page 6 of 7
manuscript critically for important intellectual content. All authors have read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 2 July 2010 Accepted: 2 September 2010
Published: 2 September 2010
References
1. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L,
Malmberg K: Glucose metabolism in patients with acute myocardial
infarction and no previous diagnosis of diabetes mellitus: a prospective
study. Lancet 2002, 359:2140-2144.
2. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L: Newly
detected abnormal glucose tolerance: an important predictor of long-
term outcome after myocardial infarction. Eur Heart J 2004, 25:1990-1997.
3. Ryden L, Standl E, Bartnik M, Van den BG, Betteridge J, de Boer MJ,
Cosentino F, Jonsson B, Laakso M, Malmberg K, Priori S, Ostergren J,
Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P,
Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K,
Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J,
Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E,
Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF,
Parhofer K, Pyorala K, Raz I, Schernthaner G, Volpe M, Wood D: Guidelines
on diabetes, pre-diabetes, and cardiovascular diseases: executive
summary. The Task Force on Diabetes and Cardiovascular Diseases of
the European Society of Cardiology (ESC) and of the European
Association for the Study of Diabetes (EASD). Eur Heart J 2007, 28:88-136.
4. Knudsen EC, Seljeflot I, Abdelnoor M, Eritsland J, Mangschau A, Arnesen H,
Andersen GO: Abnormal glucose regulation in patients with acute ST-
elevation myocardial infarction-a cohort study on 224 patients.
Cardiovasc Diabetol 2009, 8:6.
5. Libby P: Inflammation and cardiovascular disease mechanisms. Am J Clin
Nutr 2006, 83:456S-460S.
6. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis:
epidemiology, pathophysiology, and management. JAMA 2002,
287:2570-2581.
7. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O’Reilly DS,
Packard CJ, Sattar N: C-reactive protein is an independent predictor of
risk for the development of diabetes in the West of Scotland Coronary
Prevention Study. Diabetes 2002, 51:1596-1600.
8. Ziegler D: Type 2 diabetes as an inflammatory cardiovascular disorder.
Curr Mol Med 2005, 5:309-322.
9. Definition, Diagnosis and Classification of Diabetes Mellitus and its
Complication. Report of a WHO Consultation. Part 1: Diagnosis and
Classification of Diabetes Mellitus. [http://www.staff.ncl.ac.uk/philip.home/
who_dmg.pdf].
10. Definition and diagnosis of diabetes mellitus and intermediate
hyperglycaemia. Report of a WHO/IDF Consultation. [http://www.who.int/
diabetes/publications/Definition%20and%20diagnosis%20of%
20diabetes_new.pdf].
11. Gibbons RJ, Miller TD, Christian TF: Infarct size measured by single photon
emission computed tomographic imaging with (99 m)Tc-sestamibi: A
measure of the efficacy of therapy in acute myocardial infarction.
Circulation 2000, 101:101-108.
12. Kleinbaum DG, Kupper LL, Morgenstern H: Epidemiologic research. Principles
and quantitative methods New York: Van Nostrand Reinhold Company Inc
1982.
13. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC,
Vandenbroucke JP: The Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) statement: guidelines for reporting
observational studies. Lancet 2007, 370:1453-1457.
14. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M,
Quagliaro L, Ceriello A, Giugliano D: Inflammatory cytokine concentrations
are acutely increased by hyperglycemia in humans: role of oxidative
stress. Circulation 2002, 106:2067-2072.
15. Norhammar AM, Ryden L, Malmberg K: Admission plasma glucose.
Independent risk factor for long-term prognosis after myocardial
infarction even in nondiabetic patients. Diabetes Care 1999, 22:1827-1831.
16. Gasior M, Pres D, Stasik-Pres G, Lech P, Gierlotka M, Hawranek M, Wilczek K,
Szygula-Jurkiewicz B, Lekston A, Kalarus Z, Strojek K, Gumprecht J,
Polonski L: Effect of blood glucose levels on prognosis in acute
myocardial infarction in patients with and without diabetes, undergoing
percutaneous coronary intervention. Cardiol J 2008, 15:422-430.
17. Capes SE, Hunt D, Malmberg K, Gerstein HC: Stress hyperglycaemia and
increased risk of death after myocardial infarction in patients with and
without diabetes: a systematic overview. Lancet 2000, 355:773-778.
18. Solheim S, Grogaard HK, Hoffmann P, Arnesen H, Seljeflot I: Inflammatory
responses after percutaneous coronary intervention in patients with
acute myocardial infarction or stable angina pectoris. Scand J Clin Lab
Invest 2008, 68:555-562.
19. Karpinski L, Plaksej R, Derzhko R, Orda A, Witkowska M: Serum levels of
interleukin-6, interleukin-10 and C-reactive protein in patients with
myocardial infarction treated with primary angioplasty during a 6-
month follow-up. Pol Arch Med Wewn 2009, 119:115-121.
20. strom-Olsson K, Hedstrom E, Hulten LM, Wiklund O, Arheden H, Ohlin AK,
Gottsater A, Ohlin H: Dissociation of the Inflammatory Reaction following
PCI for Acute Myocardial Infarction. J Invasive Cardiol 2007, 19:452-456.
21. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein,
interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA
2001, 286:327-334.
22. Matsumori A, Furukawa Y, Hashimoto T, Yoshida A, Ono K, Shioi T,
Okada M, Iwasaki A, Nishio R, Matsushima K, Sasayama S: Plasma levels of
the monocyte chemotactic and activating factor/monocyte
chemoattractant protein-1 are elevated in patients with acute
myocardial infarction. J Mol Cell Cardiol 1997, 29:419-423.
23. Mine S, Okada Y, Tanikawa T, Kawahara C, Tabata T, Tanaka Y: Increased
expression levels of monocyte CCR2 and monocyte chemoattractant
protein-1 in patients with diabetes mellitus. Biochem Biophys Res
Commun 2006, 344:780-785.
24. Dragomir E, Simionescu M: Monocyte chemoattractant protein-1–a major
contributor to the inflammatory process associated with diabetes. Arch
Physiol Biochem 2006, 112:239-244.
25. Park KS, Ahn KJ, Kim BJ, Kim HJ, Yoo SM, Kim JY, Lee KH, Baik HW, Lee SK:
Circulating concentrations of monocyte chemoattractant protein-1 are
associated with menopause status in Korean women. Clin Chim Acta
2009, 403:92-96.
26. Braunersreuther V, Mach F, Steffens S: The specific role of chemokines in
atherosclerosis. Thromb Haemost 2007, 97:714-721.
27. Straczkowski M, Kowalska I, Nikolajuk A, Dzienis-Straczkowska S,
Szelachowska M, Kinalska I: Plasma interleukin 8 concentrations in obese
subjects with impaired glucose tolerance. Cardiovasc Diabetol 2003, 2:5.
28. Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, Meisinger C, Illig T,
Martin S, Herder C: Elevated levels of interleukin-18 predict the
development of type 2 diabetes: results from the MONICA/KORA
Augsburg Study, 1984-2002. Diabetes 2005, 54:2932-2938.
29. Derosa G, Cicero AF, Scalise F, Avanzini MA, Tinelli C, Peros E, Fogari E,
D’Angelo A: Metalloproteinases in diabetics and nondiabetics during
acute coronary syndromes and after 3 months. Endothelium 2007,
14:175-183.
30. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y,
Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N,
Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T,
Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel,
adipose-specific protein, adiponectin, in type 2 diabetic patients.
Arterioscler Thromb Vasc Biol 2000, 20:1595-1599.
doi:10.1186/1475-2840-9-47
Cite this article as: Knudsen et al.: Increased levels of CRP and MCP-1
are associated with previously unknown abnormal glucose regulation in
patients with acute STEMI: a cohort study. Cardiovascular Diabetology
2010 9:47.
Knudsen et al. Cardiovascular Diabetology 2010, 9:47
http://www.cardiab.com/content/9/1/47
Page 7 of 7

IV

